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https://doi.org/10.1016/j.ccell.2021.10.001SUMMARYADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 mul-
tiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the
mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor
molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indi-
rectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number
of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of
highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement
and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound
CD8+ T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance
and replacement of previously expanded T cell clones, but only maintenance correlates with response.
We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1
mode of action.Cancer Cell 39, 1–22, November 8, 2021 ª 2021 The Author(s). Published by Elsevier Inc. 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Clear cell renal cell carcinoma (ccRCC) is the most common
histological subtype of kidney cancer (Ricketts et al., 2018) with
a rising global incidence (Smittenaar et al., 2016). Instances of
spontaneous regression (Cole and Everson, 1956; Janiszewska
et al., 2013;SnowandSchellhammer, 1982), andefficacyof inter-
leukin-2 (Klapper et al., 2008; Rosenberg et al., 1989) and im-
mune checkpoint inhibitors (CPI) (Motzer et al., 2015, 2018; Xu
et al., 2020; Albiges et al., 2019) confirm ccRCC as an
immunogenic tumor type, though thenatureof theantigenic stim-
ulus remains unknown. ccRCC carries a modest tumor muta-
tional burden (TMB) (median of 1.42 mutations per megabase
[mut/mb]) (de Velasco et al., 2016), 10-fold lower thanmelanoma
and comparable to immune ‘‘cold’’ tumors (Alexandrov et al.,
2013). In contrast to melanoma (Snyder et al., 2014), non-small
cell lung cancer (Rizvi et al., 2015; Hellmann et al., 2018), bladder
(Aggen andDrake, 2017), and colorectal cancers (Le et al., 2015),
TMB does not associate with CPI response in ccRCC (Braun
et al., 2020; McDermott et al., 2018; Motzer et al., 2019). ccRCC
is enriched for frameshift insertion and deletions (fsINDELs) (Tur-
ajlic et al., 2017), which can generate novel open-reading frames
triggering a large number of highly distinct neoantigens.
However, so far, fsINDEL burden has not been shown to predict
benefit from CPI in ccRCC (Braun et al., 2020; McDermott et al.,
2018; Motzer et al., 2019), again in contrast to other tumor types
(Turajlic et al., 2017; Litchfield et al., 2020). Finally, an association
between mutations in PBRM1, present in 60% of ccRCC, and
response to CPI has been reported (Braun et al., 2019, 2020;
Miao et al., 2018), though the association has not been observed
consistently (McDermott et al., 2018; Motzer et al., 2019, 2020a;
Motzer et al., 2019, Abou Alaiwi et al., 2020;Motzer et al., 2020a).
Large-scale tumor transcriptome analyses show ccRCCs to
be among the most highly immune-infiltrated solid tumor types
(Ricketts et al., 2018; Rooney et al., 2015), but in contrast to other
cancers, high immune infiltration correlates with poor outcomes
following nephrectomy (Fridman et al., 2017). In the context of
treatment with CPI, high T cell/low myeloid infiltration and high
B cell abundance are reported to be enriched in responders to
atezolizumab (anti-PD-L1) (McDermott et al., 2018) and nivolu-
mab (anti-PD-1) (Helmink et al., 2020), respectively. However,
cross-validation of these features as predictive biomarkers has
yielded inconsistent findings (Bi et al., 2021; Motzer et al.,
2020a, 2020b; Braun et al., 2020), potentially owing to immune
intratumor heterogeneity (ITH) (Gulati et al., 2014; Braun et al.,
2021), especially as prior studies have relied on single tumor re-
gion evaluation. Our group has previously shown that ITH is a
frequent feature of ccRCC that associates with patterns of met-
astatic spread and outcomes following surgery (Gerlinger et al.,
2014; Turajlic et al., 2018a, 2018b). As such, ITH complicates
evaluation of prognostic and predictive biomarkers in all settings
and requires due consideration.
Our report concerns ADAPTeR (NCT02446860), a phase II, sin-
gle-arm, open-label study of nivolumab in treatment-naive pa-
tients with metastatic ccRCC. Patients underwent multiregional
tumor sampling of primary and/or metastatic sites at baseline,
week 9, at surgery (if performed), and disease progression. A
key aim of ADAPTeR was to evaluate molecular and tumor im-
mune microenvironment (TME) features throughout therapy. In2 Cancer Cell 39, 1–22, November 8, 2021addition, patientswere co-recruited to TRACERxRenal (TRAcking
Cancer Evolution through therapy[Rx]; NCT03226886), and
PEACE (Posthumous Evaluation of Advanced Cancer Environ-
ment; NCT03004755) studies to expand the spatial and temporal
breadth of profiling. We present an integrated analysis of
response to nivolumab and whole-exome and RNA sequencing
(RNA-seq), TCR profiling, and immunohistochemistry/multiple
immunofluorescence (IHC/mIF); as well as high-dimensional
flow cytometry across longitudinal, multiregion fresh tumor sam-
ples in this cohort (Figure 1A).
RESULTS
Patient characteristics and clinical benefit to nivolumab
Fifteen patients were enrolled from October 2015 to June 2018.
Demographic and clinical characteristics are shown in Table S1.
Thirteen (87%) patients had intermediate- or poor-prognostic
risk disease as defined by International Metastatic RCC Data-
base Consortium risk categorization (IMDC) (STAR Methods)
(Heng et al., 2009). At clinical data lock (December 2018), median
follow-up was 12.5 (range, 3.9 to 27.3) months. Six deaths
occurred, all due to progressive disease. The median progres-
sion-free (PFS) and overall survival (OS) were 4.1 and
22.2months, respectively. For translational analyses, we defined
patients who derived clinical benefit (hereon termed ‘‘re-
sponders’’) as those who had a partial response (PR) or stable
disease (SD), as measured by Response Evaluation Criteria
In Solid Tumors (STAR Methods) for R6 months (five patients).
Patients who derived minimal clinical benefit (hereon termed
‘‘non-responders’’) were classified by progressive disease within
6months of enrollment regardless of best response (10 patients).
Five patients (33%) had a PR, of whom one patient (ADR005) had
short-lived PR (<6 months, classified as non-responder). Six pa-
tients (40%) had SD, of which one patient (ADR011) had durable
(>6 months) SD (classified as responder) (Figure S1A; Table S1).
Two patients underwent a cytoreductive nephrectomy during the
study. We observed no association between age, sex, IMDC risk
category, and/or presence of sarcomatoid/rhabdoid features
(n = 2) and response to nivolumab (Table S1). Overall, these clin-
ical data are consistent with a larger phase II (n = 110) cohort
study of first-line pembrolizumab in patients with ccRCC
(McDermott et al., 2021).
Tumor molecular features do not correlate with
nivolumab response
All patients underwent image-guided percutaneous tumor bi-
opsies with additional archived and fresh samples collected via
TRACERx Renal and PEACE studies. Fifteen patients had pre-
treatment biopsies, and 13 patients had post-treatment bi-
opsies. In total, 115 tumor samples (fresh and archived) were
available for translational analyses (see Figure S1A for consort
diagram; Table S2 for sample characteristics). Eighty-one fresh
tumor samples and matched germline DNA underwent whole-
exome sequencing (WES). Subsequently, 22 samples were
excluded: 21 due to low tumor purity, which is expected with im-
age-guided biopsies, and one excluded due to sample contam-
ination. Fifty-nine tumor samples from 13 patients were of suffi-




Figure 1. Experimental workflow, patients and samples overview, and genomic characteristics of the ADAPTeR cohort
(A) Overview of experimental workflow. The numbers (n) of patients contributing to sample collection at different timepoints are shown.
(B) Heatmap of WES analysis demonstrating nsSNV and INDEL burden, somatic driver alterations annotated with pre/post-treatment, tumor site, IMDC risk
category, and nivolumab response. Composite mutations are annotated with dual colors. Composite mutations (two or more non-synonymous somatic mu-
tations in the same gene and tumor sample [Gorelick et al., 2020]) involving SETD2, KDM5C, and TSC2 are shown. Complex mutations in ADR002: PBRM1
frameshift insertion chr3:52584573:->T and non-frameshift deletion chr3:52584576:TAT>-; TP53missensemutation chr17:7572969:A>T and frameshift insertion
chr3:7572962:->CT. *Denotes two distinct fsINDEL mutations in one tumor sample in ADR013. See also Figures S1, S2, Tables S1, and S2.
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S2). Neither pre-treatment TMB (median 0.9 mut/mb; range
0.4–11.1), fsINDEL load (median 9; range 0–169), nor ex-
pressed non-synonymous single nucleotide variants (nsSNVs)
or fsINDELs associated with response to nivolumab (Fig-
ure S1B). Post-treatment, we found no evidence of stronger
depletion of mutations (nsSNVs or fsINDELS) that encode for
neoantigens compared with the remaining non-synonymous
mutations (Figure S1C). Molecular features of this cohortwere typical of ccRCC (Ricketts et al., 2018; Turajlic et al.,
2018b), including mutations in VHL (77%), VHL methylation in
an additional 15%, PBRM1 (62%), SETD2 (38%), BAP1
(15%), and KDM5C (38%), with both clonal and subclonal alter-
ations detected (Figure 1B). There was no association between
mutations in any gene and response to nivolumab. Copy num-
ber landscape was also typical of ccRCC with clonal loss of
3p25.3 detected in all tumors and 9p21.3 and/or 14q31.1 loss




Figure 2. Expression of HERVs and LTR-overlapping transcripts in ccRCC according to tumor purity
(A) Hierarchical clustering of patient samples according to the relative expression of HERVs previously associated with cytotoxic T cell presence, response to
immunotherapy, or the provision of antigenic epitopes.
(legend continued on next page)
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Weighted genome instability index (wGII) as a global measure
of chromosomal complexity was not predictive of nivolumab
response (p = 0.076) (Figure S1B; STAR Methods). We previ-
ously showed that ITH index, a metric developed in the context
of ex vivo multiregion sampling, was prognostic in ccRCC (Tur-
ajlic et al., 2018b). In ADAPTeR, we found no association of ITH
index and response to nivolumab (p = 0.88); however, ITH is
likely to be underestimated in this study (STAR Methods). No
driver somatic copy number alterations (SCNAs) associated
with response.
Intermetastatic heterogeneity, which can underpin differential
therapy response (Birkeland et al., 2018; Sakamoto et al., 2020;
Sveen et al., 2016; Sebagh et al., 2016), was evaluated through
postmortem sampling in three cases. Of particular interest were
the findings in ADR015. This was a patient with stage IV disease
uponenrollment intoADAPTeR, involving surgical bed recurrence,
bone metastases, and nodal disease, with a tonsillar metastasis
resected pre-treatment. PFS on nivolumab was 8.4 months (over-
all ‘‘responder’’; best response was SD evident at all sites), with
disease progression in the brain resulting in death 27.3months af-
ter trial enrollment. All metastatic deposits, including an incidental
thyroid metastasis, were sampled at postmortem and whole-
exome sequenced. We found evidence of genetic divergence be-
tween disease sites that progressed (brain) and responded (nodal
metastases) under nivolumab.Uncharacteristically highTMB (me-
dian 10.8mut/Mb) and fsINDEL load (median 166), and therefore a
high predicted neoantigen load, was evident in the progressive
brain and resected treatment-naive tonsillar metastases, but not
in treatment-responsive disease sites (median TMB 1.3mut/Mb;
fsINDEL load 8) (Figure S2A; Table S2). Most of the excess muta-
tions were contributed by C > T at GpCpN trinucleotides (Signa-
ture 15), which result from defective DNA mismatch repair
(MMRD) (Alexandrov et al., 2013). Accordingly, we detected bial-
lelic inactivation ofMLH1 (pathogenic mutation(ClinVar) with con-
current loss of heterozygosity [LOH] through canonical 3p loss, as
MLH1 is encoded at 3p22.2) in resistant, but not the nivolumab-
sensitive sites (STARMethods).MLH1 loss leads to accumulation
of a high number of mutations (Kloor and von Knebel Doeberitz,
2016), and is associated with better response to CPI (Le et al.,
2017). However, the siteswithMMRDcharacterized by nivolumab
resistance, but not the nivolumab-sensitive sites, also harbored a
beta-2-microglobulin (B2M) mutationwith LOH (FigureS2A; STAR
Methods), which can lead to loss of antigen presentation (Doherty,
1995). We confirmed loss of MLH1 and B2M protein expression
by immunohistochemistry (IHC) in resistant metastatic sites and
in a single area of the primary tumor resected 5 years before study
entry (Figure S2B). Taken together, it appears that subclonal
loss of MLH1 led to accumulation of excess neoantigens, and
subsequent loss of antigen presentation presumably due to im-
mune selective pressure. This tumor subclone was represented
in nivolumab-resistant metastases, reconciling the mixed treat-
ment response observed in this case. In ccRCC, MMRD has(B) Hierarchical clustering patient samples according to the 12 LTR-overlapping
tween responders and non-responders or affected by nivolumab.
(C) Comparisons of tumor purity. Median values are shown; top whiskers indicat
(D) Distribution plot of significant Spearman’s rank-order correlation between tum
responders and non-responders. See also Figure S3 and Table S3.been reported, albeit infrequently (Altavilla et al., 2010). However,
while loss of B2M as a mechanism of CPI resistance has been
described in other tumor types (Zaretsky et al., 2016; Gettinger
et al., 2017), this has not been described to date in ccRCC.
ccRCC-specific human endogenous retrovirus
expression reflects tumor purity and associates with
lack of response to anti-PD-1
Prior reports have indicated that the presence of intratumoral
cytotoxic T cells (Rooney et al., 2015) and response to nivolumab
(Panda et al., 2018; Smith et al., 2018; Ficial et al., 2020) in
ccRCC are associated with tumoral expression of human endog-
enous retroviruses (HERVs), suggesting they may provide a
source of cancer-specific antigens. Indeed, T cell targeting of a
member of the HERVE family has been demonstrated tomediate
regression of kidney cancer in a stem cell transplant recipient
(Takahashi et al., 2008). We therefore examined if the outcome
of nivolumab in the ADAPTeR cohort was associated with
HERV expression patterns, as determined by RNA-seq analysis.
To this end, we performed RNA-seq on 60 tumor samples, 33
pre-treatment and 27 post-treatment (week 9), representing 14
patients (see Figure S1A for consort diagram; Table S2 for sam-
ple characteristics; STAR Methods).
Prior studies (Rooney et al., 2015; Panda et al., 2018) used a
limited set of 66 HERV loci annotated by Mayer et al. (2011) or
3,173 HERV loci (Smith et al., 2018) annotated by Vargiu et al.
(2016). To allow direct comparison between these two previous
annotations, as well as with a more complete HERV annotation,
we first updated the Vargiu et al. annotation, which was based
on an earlier release of the human genome (GRCh37) to the cur-
rent release (GRCh38), and compared the coordinates of unique
elements in both annotations to a complete custom repeat region
annotation we previously built (Attig et al., 2017) (STARMethods).
This comparison revealed major discrepancies that may have
affected prior analyses. For example, HERV loci considered as
a single integration in our custom annotation were fragmented
in the Mayer et al. and/or Vargiu et al. annotations, and vice versa
(Table S3). Further, we found prior HERV annotations that were
either incomplete or extended beyond integration boundaries to
include exons of adjacent genes belonging to separate transcrip-
tion units (Figure S3A). Such discrepancies affected HERV inte-
grations previously associated with immune response in ccRCC
(e.g., ERV3-2 and ERVK-10) (Rooney et al., 2015; Smith et al.,
2018) (Figure S3A). Accounting for the above discrepancies, the
previously annotated 66 and 3,173 HERVs corresponded to
7,989 repeat loci in our custom annotation (Table S3).
None of the HERV loci previously associated with cytotoxic
T cell presence, ccRCC response to CPI, or the provision of anti-
genic epitopes (Rooney et al., 2015; Panda et al., 2018; Smith
et al., 2018; Takahashi et al., 2008) were differentially expressed
between responders and non-responders or were affected by
immunotherapy in this cohort (Figure 2A). Moreover, none of the
previously tested 7,989 HERV annotations were affected bytranscripts that were differentially expressed (R2-fold change, q % 0.05) be-
e range from third quartile to maximum. ****p < 0.0001; Mann-Whitney U test.
or purity and TPM expression of the 12 HERVs differentially expressed between
Cancer Cell 39, 1–22, November 8, 2021 5
Figure 3. GSEA and immune deconvolution by RNA-seq shows higher levels of immune infiltration and activation in responders compared
with non-responders under nivolumab
(A) Transcripts differentially regulated pre-treatment between responders and non-responders (n = 33 samples, 14 patients, negative binomial Wald test,
Benjamini-Hochberg corrected p values). A total of 3,382 transcripts were differentially regulated (false discovery rate [FDR] <0.05); the ones that overlap with the
(legend continued on next page)
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distinct loci within this limited list, distinguished responders from
non-responders, either pre- or post-treatment (R2-fold change,
q % 0.05), and half of them appeared restricted to responders
pre/post-treatment and non-responders post-treatment (Fig-
ure 2A). Thus, our analysis revealed a different pattern of HERV
association with the outcome of ccRCC immunotherapy than pre-
viously reported by others (Panda et al., 2018; Smith et al., 2018).
To investigate possible reasons of the observed associa-
tion, we re-examined tumor-cell intrinsic expression of the
selected HERVs. Many of the significantly differentially
expressed HERV loci, including those previously associated
with anti-tumor T cell responses (Rooney et al., 2015;
Panda et al., 2018) such as ERV3-2, were not specific to
ccRCC and were highly expressed in purified immune
cells (Figure S3B) (STAR Methods). For example, the LTR/
ERVK|HERVK9-intMER9a1|6|29876165|29881829 integra-
tion within the HLA locus is expressed in most immune cell
subsets and the LTR/ERV1|LTR7|1|207633751|207634199
integration is expressed in neutrophils (Figure S3B). Of note,
HERVs found to be expressed in immune cells were enriched
for members of the HERVK group (Figure S3B). It was, there-
fore, likely that association between HERVK with responders
in this study and cytotoxic T cell presence previously (Rooney
et al., 2015; Panda et al., 2018), resulted from high expression
in immune cells. In contrast, HERVs that were not expressed
in immune cells, such as the previously identified ERVE-4
(Rooney et al., 2015) and HERV 4700 (Smith et al., 2018),
were expressed at higher levels in pre-immunotherapy non-re-
sponders (Figure 2A). One exception was ERV3-2, which was
also expressed at higher levels pre-treatment in non-re-
sponders, despite also showing the highest expression in im-
mune cells, particularly neutrophils (Figures 2A and S3B).
Therefore, the association between HERV expression in bulk
tumor RNA-seq data and CPI responses may, in fact, reflect
the level and type of immune infiltration (which, in itself, is
linked with the response [McDermott et al., 2018; Motzer
et al., 2020b]).
To overcome the limitations of genomic HERV annotations, we
next quantified HERV expression in the ADAPTeR cohort using a
de novo assembled cancer transcriptome (Attig et al., 2019), and
focused on ccRCC-specific HERVs. This method takes into
consideration the structure of transcripts that overlap with repeat
elements, which allows for more accurate quantification using
transcript per million (TPM) calculations (Attig et al., 2019). Using
this method, we previously identified 570 de novo assembled
transcripts overlapping with LTR elements that were highly spe-
cific for ccRCC (Attig et al., 2019). Themajority of these transcriptsDanaher immune score gene list are labeled. No differentially regulated genes w
appears unannotated.
(B) Heatmap showing the relative expression (Z scores) of genes from eight Dan
(C) Transcripts differentially regulated post-treatment between responders and
Benjamini-Hochberg corrected p values). A total of 7,975 transcripts were differe
score gene list are labeled. No differentially regulated genes were downregulated
(D) Heatmap showing the relative expression (Z scores) of genes from eight Dan
(E) GOBP pathway analysis of genes preferentially upregulated and downregulate
pathway (hypergeometric test).
(F) Gene ontology biological process (GOBP) pathway analysis of genes preferent
number of significant genes from a pathway (hypergeometric test). See also Figuwere expressed (R0.5 TPM) in the majority of the ADAPTeR sam-
ples, but only 12 of them, from nine distinct loci, were differentially
expressed (R2-fold change, q % 0.05) between responders and
non-responders or were affected by nivolumab (Figure 2B).
Importantly, almost all of them were expressed predominantly in
non-responders pre-treatment and included the members of the
HERVE group (ERVE-4 and HERV 4700) that were previously
associated with anti-tumor T cell responses in ccRCC (Rooney
et al., 2015; Smith et al., 2018; Takahashi et al., 2008) (Figure 2B).
Thus, the use of a complete transcript assembly and TPM calcu-
lations, as opposed to normalized reads used previously, further
supported the association of ccRCC-specific LTR elements with
lack of response to anti-PD-1.
Collectively, these data suggest that transcription of HERVs
and other LTR elements that are highly specific to ccRCC were
overexpressed in non-responders pre-treatment and were
associated with an absence of ongoing anti-tumor immune re-
sponses and lack of response to anti-PD-1. As these LTR ele-
ments were selected for their specificity in ccRCC and lack of
expression in other cell types, their elevated transcription in
non-responders pre-treatment likely reflects higher tumor purity
(i.e., lower immune infiltration) compared with responders (Fig-
ure 2C). Post-treatment, ccRCC-specific HERV expression in
non-responders normalized relative to responders, consistent
with a reduction in tumor purity likely due to immune infiltration
in non-responders (Figures 2B and 2C). Accordingly, expression
of ccRCC-specific LTR element-overlapping transcripts corre-
lated with tumor purity (Figure 2D). In summary, while these
data do not exclude the provision of antigens or direct modula-
tion of the immune response, they suggest that the association
of HERV expression with CPI response reflects the cellular
composition in bulk samples in ccRCC.
Nivolumab induces T cell activation and upregulation of
TCR signaling in responders
Next, we performed differential gene expression, gene set
enrichment (GSEA), and immune subset deconvolution pre-
and post-nivolumab (STAR Methods). Tumors from responders
harbored significantly higher levels of T cells (based on Danaher
signature [Danaher et al., 2017]) both pre- and post-treatment
compared with non-responders (p = 0.019 and p = 0.038,
respectively), but T cell infiltration increased on-treatment irre-
spective of response (Figures 3A–3D and S4). We found higher
expression of CD3E, CD8A, Granzyme B (GZMB), and TCF7, in
responders compared with non-responders, particularly post-
treatment (Figure S4). ‘‘Immune-activation’’ and ‘‘TCR signaling’’
pathways were enriched in responders but not non-responders
(Figures 3E and 3F).ere downregulated between response groups, hence the left side of the plot
aher immune modules in pre-treatment samples.
non-responders (n = 27 samples, 10 patients, negative binomial Wald test,
ntially regulated (FDR <0.05); the ones that overlap with the Danaher immune
between response groups, hence the left side of the plot appears unannotated.
aher immune modules in post-treatment samples.
d pre-treatment in responders, Overlap (n), number of significant genes from a
ially upregulated and downregulated post-treatment in responders, Overlap (n),
res S4 and S5.
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https://doi.org/10.1016/j.ccell.2021.10.001Immune heterogeneity has been reported in ccRCC (Gulati
et al., 2014; Braun et al., 2021; Krishna et al., 2021) but not eval-
uated in the context of treatment. Of the 12 patients who contrib-
uted multiple samples at a single time point, three presented a
mixture of immune ‘‘hot’’ and ‘‘cold’’ biopsies at the given time
point (Figure S5). For example, in ADR005 (non-responder)
pre-treatment, one biopsy from primary tumor was immune
‘‘hot’’ and four (two from primary tumor and two from a lung
metastasis) were immune ‘‘cold.’’ Post-treatment, two biopsies
(representative of previously ‘‘cold’’ lung metastasis) were im-
mune ‘‘hot,’’ consistent with nivolumab-induced immune infiltra-
tion. In ADR013 (responder), longitudinal sampling of the primary
tumor showed the two pre-treatment biopsies were immune
‘‘cold,’’ while post-treatment, five biopsies were ‘‘hot’’ and one
was ‘‘cold’’ (Figures 3B, 3D, and S5). On review of hematoxylin
and eosin (H&E) images, the one immune ‘‘cold’’ post-treatment
biopsy was mostly necrotic, likely reflecting nivolumab
response. These two cases demonstrate that immune heteroge-
neity is both inherent to ccRCC pre-treatment and altered by CPI
and response post-treatment. ADR003 was the only case with
consistently immune ‘‘hot’’ baseline biopsies by RNA-seq yet
was a non-responder. Review of H&E revealed distinct immune
‘‘deserted’’ and heavily infiltrated areas within a single sample.
In this case, it remains possible that clones evading immune
recognition/infiltration, unaccountable by bulk-RNA-seq, may
have driven the patient’s outcome. Taken together, these
examples highlight challenges in patient stratification by
immune infiltration status in ccRCC, especially with single-sam-
ple approaches.
Finally, we evaluated the association between published gene
expression signatures and nivolumab response (STAR Methods).
IMmotion150 study Teff
high signature (McDermott et al., 2018), but
not Teff
high/Myeloidlow signature was enriched in responders
compared with non-responders (p = 0.042 and p = 0.038 pre-
and post-treatment, respectively) (Figure S4). The 26-gene
Javelin101 signature (Motzer et al., 2020b)was also enriched in re-
sponders compared with non-responders (p = 0.028 and p =
0.038 pre- and post-treatment, respectively). Cross-validation of
these gene expression signatures in other single-sample studies
have yielded inconsistent findings (Motzer et al., 2020a, 2020b;
Braun et al., 2020; Krishna et al., 2021). In contrast, the signatures
performed consistently in our multiregion cohort, despite inherent
differences across studies in treatment regimens and type of tis-
sue that was profiled.
CD8+ T cells upregulate GZMB following nivolumab in
responders
Next, to evaluate dynamic TME changes under nivolumab with
greater resolution, we applied antibody panels (immunohisto-
chemistry [IHC] and multiplex immunofluorescence [mIF];
STAR Methods) focused on T cells, macrophages (McDermott
et al., 2018; Bi et al., 2021), B cells, and plasma cells (Helmink
et al., 2020; Petitprez et al., 2020) to 61 formalin-fixed paraffin-
embedded tumor samples (41 pre-treatment; 20 post-treatment)
from 14 patients (Figure S1A; STAR Methods).
We observed no difference in T cell number (CD8+, CD4+,
CD8+CD4+, or T regulatory cells [Tregs]), CD8+/Treg and
CD4+effector/Treg ratio, or total PD-1 expression between
response groups, at any time point (Figures 4A, 4B, and S6A–8 Cancer Cell 39, 1–22, November 8, 2021S6C). Low levels of GZMB expression were observed prior to
treatment in both responders and non-responders; however,
post-treatment (week 9), both overall (p = 0.024) and CD8+
T cell-specific GZMB expression (p = 0.047) significantly
increased in responders compared with non-responders (Fig-
ures 4B, 4C, and S6D). The level of CD163+ myeloid cells alone
or as a ratio to T cells (CD3+/CD163+ and CD8+/CD163+) did not
associate with response (Figures 4A and S6C). We observed
significantly more B cells in responders (p = 0.02) (Figure 4A) at
baseline, consistent with prior reports (Helmink et al., 2020),
but not on-treatment. There were no differences in the number
of plasma cells between response groups at any time point (Fig-
ures 4A and S6A).
We note observations made from bulk RNA-seq and IHC/mIF
data showed trends that were in the same direction but did not
always reach statistical significance in some instances. For
example, increased B cells and higher GZMB expression in re-
sponderswas evident by both IHC/mIF andRNA-seq (Figure S4),
but only statistically significant by IHC/mIF. CD4+/8+ T cell
numbers and PD-1 expression were not statistically different
by IHC/mIF between response groups but were significantly en-
riched in responders by RNA-seq. These findings reflect the
known imperfect correlation between protein and mRNA levels
for many genes and limitations of immune classification by
bulk RNA-seq (Newman et al., 2015; Braun et al., 2020), as
compared with the single-cell resolution afforded by histology-
based methods.
Maintenance of previously expanded TCR clones and
CDR3 clustering supports ongoing antigen-driven
stimulation of pre-existing T cells in responders
The question of whether tumor-specific T cells activated by CPI
pre-exist in the tumor or are replaced by new T cell clones re-
cruited to the TME remains under debate (Riaz et al., 2017;
Cha et al., 2014; Wu et al., 2020; Li et al., 2019b) and has not
been investigated in the context of ccRCC. Crucially, this ques-
tion can only be addressed with paired pre- and post-treatment
samples, such as those in ADAPTeR. We sequenced the b-chain
TCR repertoires from 14 patients pre- and post-treatment,
including 64 tumor and 29 peripheral blood mononuclear cell
(PBMC) samples (Figure S1A; STAR Methods). To quantify
TCR heterogeneity within each patient, described in other can-
cer types (Joshi et al., 2019; Zhang et al., 2018a; Angelova
et al., 2018), we performed pairwise comparison of TCR reper-
toires of multiple samples from each time point for each patient
(STAR Methods). TCR repertoire similarity varied, from near-
complete concordance between biopsies in some patients, to
minimal overlap in others (Figures S7A and S7B). To mitigate
against the effects of TCR heterogeneity in the cohort-level anal-
ysis, we pooled TCR sequences from multiple tumor regions
taken at each time point for each patient.
Cohort-wide, the median number of unique b-chain tran-
scripts in tumor and blood samples was 3,644 and 21,370,
respectively. We quantified TCR clonality through a ‘‘repertoire
clonality score,’’ where low scores correlate with more diverse
repertoire and high scores with expansion of dominant TCR
clones (STAR Methods). Overall, TCR clonality was higher in tu-
mor samples compared with PBMCs (Figure 5A), likely reflect-




Figure 4. Quantification and immunopheno-
typing of pre- and post-treatment infiltrating
immune cells by IHC and mIF
(A) Comparison of T cell subset (out of total T cells),
CD163+ myeloid cells, B cell and plasma cell infil-
tration in treatment-naive samples in responders
(n = 5) and non-responders (n = 9) is shown on the
left. On the right is the ratio between CD3+ (total
T cells) and CD163+ myeloid cells and CD8+ and
CD163+ cells at baseline. B cell and plasma cell
scoring was done by using IHC. Other markers were
scored by using IF. IHC images of representative
responder and non-responder patients pre-treat-
ment showing B cell (blue), PD-1+ cells (yellow), and
plasma cells (magenta) infiltration.
(B) Level of overall GZMB, GZMB+CD8+, and overall
PD-1 expression in responders and non-responders
in treatment-naive and on-treatment samples is
shown. PD-1 staining was performed with IHC. All
other markers were stained with IF.
(C) mIF images showing GZMB+CD8+ cells in a
representative responder and non-responder pa-
tient at baseline and post-nivolumab treatment.
Median values were used for each patient and a
two-sidedMann-WhitneyU statistical test was used
for the analysis. *p < 0.05. See also Figure S6.
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B Figure 5. TCR-seq demonstrates maintained
clonal expansion through persistent anti-
genic stimulation associate with nivolumab
response
(A) The intratumoral and peripheral TCR repertoire
clonality scores are shown for each patient at each
time point.
(B) The intratumoral TCR repertoire clonality scores
pre-treatment are shown for each patient, catego-
rized by response to nivolumab. Mixed-effect model
p value shown.
(C) Correlated clone sizes in tumor samples. Scat-
terplots of tumor clone size pre- and post-treatment
are shown for all patients. Clones are colored by
expansion/contraction status (STAR Methods).
(D) The intratumoral similarity (cosine) scores be-
tween pre-treatment (red) and on-treatment (blue)
are shown for each patient (n = 12). Patients are split
between responders and non-responders. Re-
sponding patients exhibit greater cosine score, with
the two-sided Mann-Whitney test p value shown.
(E) The frequency distribution of the intratumoral
expanded TCRs pre-treatment (red circles; n = 469
individual TCRs combined from 12 patients) and
post-treatment (blue circles). Only TCRs that were
detected post-treatment were included.
(F) The clustering algorithm was run on all patients,
and the pre-treatment normalized number of clus-
ters for the networks containing expanded se-
quences is shown. Two-sided Mann-Whitney test
p value shown; n = 14 patients. The minimum and
maximum are indicated by the extreme points of
the box plot; the median is indicated by the thick
horizontal line; and the first and third quartiles are
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https://doi.org/10.1016/j.ccell.2021.10.001intratumoral TCR clonality in responders compared with non-
responders (p = 0.042) (Figure 5B), but post-treatment the
difference was not significant (p = 0.25) (Figure S7C). Peripheral
TCR clonality was not associated with response at any
time point (Figure S7D). The number of clonotypes that
increased in frequency (‘‘expansion’’) or decreased in fre-
quency (‘‘contraction’’) post-treatment were not significantly
different between response groups, intratumorally or peripher-
ally (Figures 5C, S7E, and S7F).
Next, we computed a cosine score that reflected how similar
TCR repertoires were pre- and post-treatment (STAR Methods),
to evaluate the link between nivolumab response and mainte-
nance of pre-existing or replacement with novel TCR clonotypes.10 Cancer Cell 39, 1–22, November 8, 2021Tracking the total TCR repertoires, we
observed a greater degree of TCR clonal
maintenance in responders (greater TCR
repertoire similarity between timepoints)
compared with non-responders intratu-
morally (p = 0.024) (Figure 5D), but not in
PBMCs (Figure S7G). In particular, pre-
existing expanded TCR clones were
more likely to be maintained in responders
compared with non-responders, where
they were frequently replaced (p = 0.024,
Figures 5E and S8A). The appearance ofnovel expanded T cell clones post anti-PD-1 did not correlate
with response to nivolumab (Figure S7E).
Given the broader debate around TCR clonal dynamics and
CPI response, we reanalyzed longitudinal TCR-sequencing
(TCR-seq) data from a study by Yost et al. (2019) (see Table S4
for patient, treatment, and sample characteristics; STAR
Methods). This study reported the appearance of novel
expanded T cell clones, with an activated and exhausted pheno-
type and enhanced TCF7 expression following anti-PD-1 treat-
ment for metastatic basal cell carcinoma. However, associations
with clinical response were not investigated. We identified
expanded TCRs present pre-treatment and tracked them post-
treatment. We observed a trend for increased maintenance of
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https://doi.org/10.1016/j.ccell.2021.10.001expanded pre-existing clones in anti-PD-1 responders (p = 0.08)
(Figure S8B), consistent with our findings in ADAPTeR. Taken
together, these findings in two different indications suggest
that anti-PD-1 is able to both expand novel T cell clones (likely
driven by new T cell priming) and maintain previously expanded
T cell clones, but only the latter appears to directly associate with
clinical outcomes. Evaluation in larger datasets across tumor
types with longitudinal tumor samples are needed to establish
if TCR clonal maintenance is a universal feature of anti-PD-1
responders.
Antigen-specific T cell responses are often associatedwith the
presence of clusters of TCRs with similar CDR3 peptide binding
sequences (Dash et al., 2017; Glanville et al., 2017). We per-
formed clonotype clustering analysis (STAR Methods) in the
ADAPTeR cohort, and observed that expanded TCR clones
showed a trend toward increased clustering of similar CDR3 se-
quences (or ‘‘cluster structure’’) in responders compared with
non-responders, both pre- and post-treatment (p = 0.06 and
0.07, respectively) (Figures 5F and S8C). At baseline, expanded
TCRs that were maintained displayed significantly more cluster
structure than expanded TCRs that were replaced (p = 0.008,
Figures S8C–S8E). Taken together, these data suggest that in re-
sponders, there is a population of TCR clonotypes that have
expanded in the tumor pre-treatment, and are preferentially
maintained by anti-PD-1 treatment, perhaps reflecting enhanced
stimulation by persistent antigen(s) and the ability of anti-PD-1 to
prevent disappearance of such cells likely though prevention of
programmed cell death (Wei et al., 2018). In non-responders,
there was less TCR expansion pre-treatment and there was a
more dynamic process of TCR replacement post-treatment,
perhaps reflecting a lack of persistent antigen stimulation.
Finally, to investigate TCR repertoires across space and time,
we performed TCR-seq on five disease sites in a patient enrolled
in ADAPTeR who also underwent postmortem sampling
(ADR005). This patient presented a mixed picture in that primary
tumor and lung metastases maintained response to nivolumab
until death; while new brain, bone, and thoraco-nodal metasta-
ses emerged on nivolumab, presenting sites of immune escape
(Figure S9A). Five TCR clones were expanded pre-nivolumab in
the primary tumor and lung metastasis and detected on-treat-
ment (week 9). Following death, three of the five clones were
maintained and expanded in non-progressive disease sites (pri-
mary tumor and lung), and none were detectable in the progress-
ing sites (brain, bone, and thoraco-nodal metastases) (Figures
S2D and S9B). Primary tumor, lung, and brain metastases
were genetically similar, sharing 74% of all nsSNV/fsINDELs
(Figures 1B and S9C). Of the 25 neoantigen-encoding mutations
(55 predicted neoantigen-HLA binding pairs), eight were ex-
pressed across primary tumor, lung, and brain metastases
(Figure S9B). Three neoantigen-encoding mutations (with five
predicted neoantigen-HLA binding pairs) were exclusive to nivo-
lumab-responsive sites, but relevance of this finding is unclear
without direct confirmation of immune reactivity.
Nivolumab binds pre-expanded CD8+ T cells and
induces a cytotoxic phenotype in responders
To further characterize the CD8+ T cells exhibiting features of an-
tigen engagement and potentially impacted by PD-1 blockade,
we next sought to evaluate the transcriptional program of nivolu-mab-bound CD8+ T cells in samples obtained post therapeutic
intervention. Due to large amounts of fresh tissue required for
this analysis, it was only feasible in the two patients who under-
went week 9 cytoreductive nephrectomy per study protocol. We
derived and pooled single-cell suspensions of tumor-infiltrating
lymphocytes from six spatially distinct regions of the nephrec-
tomy specimens from ADR013 (responder) and ADR001 (non-
responder) sorted nivolumab-bound CD8+ T cells and analyzed
them via high-dimensional flow cytometry and single-cell RNA
(scRNA-seq) and single-cell TCR (scTCR-seq) sequencing
(STAR Methods). Detection of nivolumab (human immunoglob-
ulin [Ig]G4) bound to cells with anti-IgG4 antibodies has previ-
ously been shown as a robust tool to evaluate PD-1 receptor oc-
cupancy by anti-PD-1 antibodies (Brahmer et al., 2010; Huang
et al., 2017). We established the technical feasibility for detection
of nivolumab-bound cells in a competition assay where IgG4
identified T cells bound to pembrolizumab (anti-PD-1 antibody)
(Figure S10; STAR Methods) and applied this method to down-
stream assays in ADAPTeR.
Nivolumab-bound (IgG4+) CD8+ T cells showed higher expres-
sion of GZMB (38.9% versus 8.75%), TCF7 (19.5% and 2.17%),
CD39 (54.6% versus 3.25%), TOX (14.5% versus 4.10%), and
TIM3 (35.4% versus 3.52%) in ADR013 (responder) compared
with ADR001 (non-responder) (Figure S11). This suggests that
nivolumab-bound CD8+ T cells in the responder have a cytotoxic
and progenitor-like phenotype (Ghorani et al., 2020; Miller et al.,
2019; Wang et al., 2019; Kallies et al., 2020; Khan et al., 2019;
Sekine et al., 2020; Yao et al., 2019; Zhao et al., 2021) and are
likely tumor-reactive (Duhen et al., 2018; Simoni et al., 2018)
(Table S5), despite upregulating markers of dysfunction. We
also detected unbound PD-1 on nivolumab-bound CD8+
T cells in ADR013 (20.9%) and ADR001 (0.78%) (Figure S11),
possibly indicating further PD-1 upregulation following nivolu-
mab binding and TCR stimulation, i.e., as activation (Dong
et al., 1999; Barber et al., 2006), particularly in the responder,
rather than incomplete receptor occupancy.
Next, we performed paired single-cell RNA and TCR-seq
(scRNA/TCR-seq), on the nivolumab-bound T cells (STAR
Methods). scRNA-seq was annotated with the corresponding
VDJ information for each cell and then merged. Cells were
classed as CD8 (CD8+CD4FOXP3), CD4 (CD8CD4+FOXP3)
and Tregs (CD8FOXP3+) (Figure S12A; STAR Methods). We
observed similar levels of CD8+ T cells, but lower proportions
of Tregs in ADR013 (responder) compared with ADR001 (Fig-
ure S12B). Differential gene and gene set enrichment analyses
of nivolumab-bound CD8+ T cells showed upregulated pro-in-
flammatory cyto/chemokine genes and T cell activation path-
ways in both cases (Figures 6A and S12C), irrespective of clinical
response to nivolumab. We observed hyperexpanded CD8+
clones (defined as 200–1000 TCR clones with the same CDR3
sequence) in ADR013 but not in ADR001, where TCR expansion
was limited (no expansion (singletons) to <200 clones) (Figures
6B and 6C). Further, expanded nivolumab-bound CD8+ T cells
in ADR013 expressed higher levels of GZMK compared with
ADR001 (Figures 6D and S12D). scRNA-seq data confirmed
higher expression of GZMB, TCF7, TIM3, and CD39 expression
in ADR013 on nivolumab-bound CD8+ T cells observed with flow
cytometry (Figure S13). The proportion of nivolumab-bound







Figure 6. Nivolumab binding correlates with upregulation of T cell activation genes and clones expanded through persistent antigenic
stimulation
(A) GOBP pathway analysis of genes preferentially upregulated in drug-bound CD8+ cells in ADR001 (non-responder) and ADR013 (responder), circle size
indicative of number of genes overlapping with GOBP term.
(B) Uniform manifold approximation and projection (UMAP) of scRNA-seq data from non-responder and responder colored by frequency of clone.
(C) Clonal proportion plot of CD8, CD4 effector, and Treg compartments in non-responder and responder.
(D) Heatmaps showing top genes which positively correlated (Pearson’s correlation, CD8+ cells only) with TCR expansion in the responder.
(E) Proportion of cells in each expansion class that are nivolumab-bound or unbound.
(F) Representative network diagrams of post-treatment intratumoral CDR3 b-chain sequences for ADR001 and ADR013. Clusteringwas performedwithin the bulk
TCR-seq data around expanded intratumoral TCRs, subdivided between clones that were expanded in the post-treatment repertoire exclusively (blue circles)
and clones that were also expanded pre-treatment (orange circles). The network shows clusters for which at least one CDR3 was also detected in the scTCR
repertoire. IgG4 negative clones that were detected in the scTCR repertoire but not expanded in the bulk TCR repertoire and are represented (yellow circle). The
network was then split between clones that were mapping to a majority of IgG4 negative cells (top) or a majority of IgG4 positive cells (bottom) in the single-cell
data. Clustering networks derived from bulk post-treatment tissue are shown (gray circles). See also Figures S10–S13 and Table S5.
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https://doi.org/10.1016/j.ccell.2021.10.001that nivolumab binding leads to clonal expansion. T cell activa-
tion/dysfunction of nivolumab-bound cells, determined by pub-
licly available gene signature of T cell states (STAR Methods)
was evident in both patients, higher in ADR013, consistent with
increased TCR stimulation of nivolumab-bound T cells in the
responder (Figure S12E; STAR Methods).
Combining bulk and single-cell TCR-seq datasets, we evalu-
ated if the expanded clones post-treatment (1) displayed cluster
structure; (2) if clustered clones were drug-bound; and (3) if clus-
tered, drug-bound clones were novel or pre-existing. We con-
structed cluster networks for ADR013 and ADR001 (STAR
Methods), and defined each TCR clone within the networks by
drug-binding status (IgG4+ or IgG4). Then, we used pre/post-
treatment bulk TCR-seq data to derive ‘‘novel’’ or ‘‘pre-existing’’
labels for each clone that was captured post-treatment by
scTCR-seq (Figure 6F). In ADR013 (responder), expanded
clones were clustered and mostly (89%) drug-bound, consisting
of both pre-existing and novel TCRs (Figure 6F). By contrast,
there was an overall paucity of expanded or clustered TCRs in
ADR001 (non-responder), either novel or pre-existing (Figure 6F).
This is consistent with the post-treatment bulk-level data in this
patient and at cohort-level, where non-responders are charac-
terized by clonal replacement of expanded TCRs. This limits
inference on the relationship between clustering and drug-bind-
ing at the single-cell level in this non-responder patient.
While scRNA/TCR-seq data were derived from only two pa-
tients, they recapitulate the findings at the cohort-level data
and provide further evidence for reinvigoration of pre-existing
CD8+ T cells in responders. Critically, the data provide direct ev-
idence that intratumoral T cells in a responding patient were
expanded, PD-1 expressing, and nivolumab binding, and had
a more activated phenotype, distinct from CD8+ T cells in the
non-responder.
Meta-analysis of >100,000CD8+ T cells reveal expanded
TCRs and GZMB/K upregulation in responders to CPI
Next, we sought to validate our findings in additional datasets.
Three studies have reported ccRCC single-cell profiles across
disease stages (Braun et al., 2021; Borcherding et al., 2021) or
in the context of ipilimumab (anti-CTLA4) plus nivolumab
(Krishna et al., 2021). Cohorts reported by Braun et al. (2021)
(n = 12) andBorcherding et al. (2021) (n = 3) were treatment-naive
patients, whereas Krishna et al. (2021) (n = 6) reported on pa-
tients treated with nivolumab (n = 1) or ipilimumab plus nivolu-
mab (n = 3). We performed a meta-analysis of scRNA/TCR-seq
data across these published studies (Braun et al., 2021; Krishna
et al., 2021; Borcherding et al., 2021), as well as ADAPTeR, eval-
uating 45 tumor regions from 23 patients, totaling 159,688 cells
after filtering for CD8/CD4/Treg cells (see Table S6 for patient,
treatment, and sample characteristics; STARMethods). As these
samples were taken at single timepoints, longitudinal changes
could not be assessed. To maximize comparability across co-
horts, we applied a harmonized definition of CPI response
(PFS >6 months on CPI classed as ‘‘responder’’; PFS <6 months
as ‘‘non-responder’’) and TCR expansion (STAR Methods). In
total, we collated scRNA profiles from 159,688 cells and TCR
clonotypes from 21,053 cells, representing CD8 (n = 109,294),
CD4 (n = 41,247) and Treg (n = 9,147) cells (Figures 7A, S14A,
and S14B).TCR clonal expansion was highly variable across disease
stages (I-IV) butwere typically grouped according toCPI response
(higher in responders comparedwith the non-responder; p = 0.38)
(Figures 7B and 7C). Among the responders, patient t4was a clear
outlier among the responders with a low degree of TCR clonal
expansion, likely reflecting low CD8+ T cell (n = 1,631) and TCR
capture (detected in 16% of cells) in these samples, compared
with cohort median (3,856 CD8+ T cells and 59% TCR detec-
tion rate).
Evaluating all TCR clones, we observed higher expression of
GZMB, PDCD1 (PD-1), HAVCR2 (TIM-3), and ENTPD1 (CD39)
in CD8+ T cells from patients treated with CPI compared with un-
treated patients (Figure S14A), and in CPI-responders compared
with non-responders (Figure S14B). Expanded TCR clones had
higher expression of activation (i.e., GZMB, IFNG, HLA-DR,
CCL3) and immune checkpoint markers (i.e., HAVCR2, LAG3,
CTLA4) (Figure S14C). Expanded TCRs in responders but not
the non-responder showed upregulation of CD137 (TNSFR9,
4-1BB), a co-stimulatory molecule that interacts with antigen-
presenting cells to support T cell anti-tumor activity (Ye et al.,
2014; Thommen and Schumacher, 2018) and express GZMK
(Figure 7D). Despite inherent differences in timing of sampling
and CPI regimens across these cohorts, the data are consistent
with the preferentially expansion of activated/exhausted CD8+
T cells in responders to PD-1 blockade (Figure 8).
DISCUSSION
We present results of a phase II study and multi-omic analysis of
advanced stage ccRCC through treatment that sheds light on
the determinants of anti-PD-1 response and resistance, and in
particular the nature of the CD8+ T cells likely contributing to
anti-tumor immunity.
No single mutation, SCNA, nor TMB and INDEL load associ-
ated with response in accordance with prior studies (Braun
et al., 2020; McDermott et al., 2018; Motzer et al., 2020b),
although our small cohort size was likely underpowered to
robustly detect response associations with genomic alterations.
The question about the contribution of mutations or SCNA
events to anti-tumor immunity in ccRCC remains incompletely
understood. A notable exception was a case with excessively
high TMB mediated by MMRD, and B2M was likely selected to
provide immune escape after these sites acquired MMRD/
high neoantigen load. Decreased MHC-I expression associates
with reduced PFS with avelumab (anti-PD-L1) plus axitinib
(anti-vascular endothelial growth factor) in ccRCC (Motzer
et al., 2020b), but the frequency and impact of loss of antigen
presentation is undefined. The role of mutations in forming neo-
antigens in ccRCC remains unclear, but we note reports of T cell
reactivities tomutant peptides both from point mutations and IN-
DELs (Rahma et al., 2010). The difficulty in linking mutations,
especially fsINDELs, to response may lie in the accuracy of
variant calling, and overall low response rate to anti-PD-1
monotherapy.
We show that HERVs frequently associated with T cell infil-
tration in bulk tumor biopsies (Rooney et al., 2015; Panda
et al., 2018; Smith et al., 2018; Takahashi et al., 2008), such
as ERV3-2 and ERVK-10, are highly expressed in immune
cells. This offers a more parsimonious explanation forCancer Cell 39, 1–22, November 8, 2021 13
Figure 7. Meta-analysis of scRNA/TCR-seq data across Braun et al., Krishna et al., Borcherding et al., and ADAPTeR cohorts
(A) Uniform manifold approximation and projection (UMAP) of merged CD8+ (CD8+/CD4/FOXP3), CD4+ effector (CD8/CD4+/FOXP3), and Treg (CD8/
FOXP3+) cells from four cohorts: Braun et al., Krishna et al., Borcherding et al., and ADAPTeR (ADR001 and ADR013), colored by cell types.
(B) UMAP of scTCR-seq data of all cohorts colored by TCR expansions status (expanded or singleton clonotypes). Only CD8+ T cells are represented in color, NA
denotes CD4+ T cells, Tregs, and unannotated CD8+ TCR clones (STAR Methods).
(C) The TCR clonal expansion index is shown for each patient (median value of multiple regions for each patient where applicable). Patients are split between
responders and non-responders of CPI treatment, or no CPI treatment. Disease stages (I–IV) are annotated. Only CD8+ T cell data are shown. Patient annotations
from each cohort are: ADAPTeR – ADR013 (responder), ADR001 (non-responder); Brocherding et al. – GU0700, GU0744, GU0715; Braun et al. – S1, S2, S3, S5,
S6, S7, S8, S11, S12, S14, S15, S16; Krishna et al. – t1, t2, t3, t4, UT1, UT2. Two-sided Mann-Whitney test p value shown; n = 23 patients. The minimum and
maximum are indicated by the extreme points of the box plot; the median is indicated by the thick horizontal line; and the first and third quartiles are indicated by
box edges.
(D) Principal component analysis (PCA) analysis shows the differential gene expression pattern in expanded and non-expanded TCRs in CD8 cells based on CPI
treatment and response status in the Braun et al., Krishna et al., Borcherding et al., and ADAPTeR cohorts. See also Figure S14.
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https://doi.org/10.1016/j.ccell.2021.10.001previously described associations to both T cell infiltration
and CPI response. We found previous HERV nomination
methods were problematic (fragmented, incomplete, or
multi-gene spanning transcripts) and this is an additional bar-
rier to HERV signatures translating to a clinical predictive
biomarker. We confirmed that ERVE-4 and HERV4700 are
ccRCC-specific, consistent with studies demonstrating direct
T cell reactivity to these specific HERVs (Takahashi et al.,
2008). While they did not associate with nivolumab response
in this cohort, we note that T cell responses targeting these
HERVs are HLA-A*02 and HLA-A*11 restricted (Smith et al.,
2018; Cherkasova et al., 2016), and consequently, a positive
correlation with the outcome of immunotherapy would only
be expected in patients with this HLA allele. Overall, these
findings have implications for approaches in ongoing CPI-
biomarker discovery and potential therapeutic targeting of
HERVs in ccRCC.
While the source of antigenic stimulus in ccRCC remains
elusive, antigen-agnostic evaluation of TCR repertoire offered14 Cancer Cell 39, 1–22, November 8, 2021new and relevant insight into the impact of anti-PD-1 on T cell
responses. Among these, the existence of a tumor-specific
T cell response is supported by our findings of pre-existing,
expanded CD8+ T cell clones in responders, and the mainte-
nance of these expanded CD8+ T cell clones characterizes
response to nivolumab. These findings, which were directly
demonstrated using our longitudinal samples, validate the
previous report of expanded tissue-resident T cells in a CPI
responder inferred from pseudotime analysis of post-treat-
ment single-cell data (Krishna et al., 2021). Moreover, while
previous studies have demonstrated that TCR clonality varies
considerably across disease stages (Braun et al., 2021), our
data identify baseline pre-treatment TCR clonality as a predic-
tor of a clinical response to anti-PD-1. This observation of
a potential biomarker may be important in the adjuvant
setting, given phase III clinical trial data (KEYNOTE-564;
NCT03142334) showing improved disease-free survival in pa-
tients with high-risk resected ccRCC receiving pembrolizu-
mab (Choueiri et al., 2021).
Figure 8. Longitudinal profiling by bulk and single-cell RNA/TCR-seq reveal dynamic immune correlates of response and resistance to
nivolumab.
(1) Clonally expanded CD8+ T cells pre-treatment in ADR013 (responder). High TCR clonality. (2) Maintenance of pre-existing clonally expanded and expansion of
novel CD8+ T cells under nivolumab. Drug-binding activates CD8+ T cells during therapy response. (3) Limited clonal expansion of CD8+ T cells pre-treatment in
non-responders. Low TCR clonality. (4) Replacement of expanded CD8+ T cells under nivolumab. Drug-binding occurs on CD8+ T cells that lack a cytotoxic
phenotype and tumor progression ensues.
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https://doi.org/10.1016/j.ccell.2021.10.001We show that on-treatment change in GZMB expression is
a dynamic biomarker of nivolumab in ccRCC, and increase in
TCF7+CD8+ T cells and B cells also correlated with response
in our cohort. While we acknowledge that these findings
would benefit from validation with larger longitudinal datasets,
GZMB has also demonstrated predictive utility for neoadju-
vant avelumab in bladder cancer (Powles et al., 2019), and a
prior report in ccRCC has shown TCF7+CD8+ T cell can be
activated in vitro, and could maintain a progenitor-like state
when located within antigen presentation niches (Jansen
et al., 2019). Higher CD8+ T cell density at tumor invasive
margin has been reported to associate with longer PFS with
avelumab plus axitinib in ccRCC (Motzer et al., 2020b). As
such, further work to characterize the interaction between
co-located B and T cells, especially at tumor margins, will
be critical.
There are limitations to our study. First, the small number of
patients limit data generalizability, and findings from this studywould benefit from validation in larger datasets; however, our
scope for discovery was afforded by a broadened sampling
frame (multiregion and multi-metastatic site biopsies) and longi-
tudinally tracking of molecular and tumor immune microenvi-
ronment (TIME) changes under therapy. Samples from only
two patients underwent multiparameter flow cytometry and
scRNA/TCR-seq analyses in our study, and results remain
exploratory. While this facilitated high-resolution cellular char-
acterization, spatial relationship with other immune cells was
not evaluable. Looking forward, spatial transcriptomic profiling
techniques with single-cell sensitivity (Merritt et al., 2020; Ro-
driques et al., 2019) will be valuable in studying TIME evolution
in ccRCC. Finally, while results from the meta-analysis support
findings in ADAPTeR, cross-study differences in cohort and
treatment characteristics remain a key consideration to inter-
pretation of these results, including the possibility that the addi-
tion of ipilimumab in the Krishna et al. (2021) cohort may
confound observed immune responses.Cancer Cell 39, 1–22, November 8, 2021 15
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https://doi.org/10.1016/j.ccell.2021.10.001In conclusion, in this prospective study, we reveal features of
anti-PD-1 response and resistance in ccRCC. We identified tu-
mor-specific T cells with cytotoxic features in ccRCC, which
hold promise for development of adoptive cellular therapy for
this cancer (Wong et al., 2017). While the treatment landscape
has evolved to include combination therapies (Albiges et al.,
2019), this dissection of immune changes under nivolumab pro-
vides the foundation for understanding response to combination
therapies, and is relevant to the application of anti-PD-1 in the
adjuvant setting (Choueiri et al., 2021). Finally, our multi-omic
analysis framework provides a template and highlights chal-
lenges for future immuno-oncology biomarker studies in ccRCC.STAR+METHODS
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Deposited data
Multi-region whole-exome sequencing data on ADAPTeR
patient cohort.
This study EGAS00001005638
Multi-region RNA-seq data on ADAPTeR patient cohort. This study EGAD00001008163
Multi-region TCR-seq data on ADAPTeR patient cohort. This study EGAD00001008165
Multi-region single-cell RNA and TCR-seq data on
ADAPTeR patients.
This study EGAD00001008166
Multi-region single-cell RNA and TCR-seq single-cell count
matrices, VDJ annotations, and metadata on ADAPTeR
patients
This study https://doi.org/10.5522/04/16573640.v1
Multi-region processed bulk-TCR sequence data This study https://doi.org/10.5522/04/16571573.v1
Next generation sequencing of human immune cell
subsets across diseases
Linsley et al., 2014 GSE60424
RNA-seq of human AML, CMML and MDS CD34+ blast
cells, CD4+ T cells and CD8+ T cells treated with 5-aza
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Kazachenka et al., 2019 E-MTAB-8208
Yost et al. cohort TCRseq data derived from tumours
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carcinoma pre- and post-anti-PD-1 treatment
Yost et al., 2019 https://doi.org/10.21417/KY2019NM;
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yost-2019-natmed
Braun et al. cohort scRNA/TCRseq data derived from
tumour samples from patients with stage I-IV ccRCC
Braun et al., 2021 Downloaded from the published
supplemental data
Borcherding et al. cohort scRNA/TCRseq data derived
from tumour samples from patients with stage I-III ccRCC
Borcherding et al., 2021 GSE121638
Krishna et al. cohort scRNA/TCRseq data derived from
tumour samples from patients with stage III & IV ccRCC
Krishna et al., 2021 https://trace.ncbi.nlm.nih.gov/Traces/sra/
sra.cgi?analysis=SRZ190804
Oligonucleotides
Oligonucleotide sequences for VHL methylation-specific
PCR see STAR Methods
This study N/A
Oligonucleotide sequences for B2M specific PCR to detect
mutations by Sanger sequencing see STAR Methods
This study N/A
Software and algorithms
Burrows-Wheeler Aligner (BWA) v0.7.15 Li and Durbin, 2009 http://bio-bwa.sourceforge.net/
Samtools v1.3.1 Li and Durbin, 2009 http://samtools.sourceforge.net/
Picard v1.81 N/A http://broadinstitute.github.io/picard/
Mutect v1.1.7 Cibulskis et al., 2013 http://archive.broadinstitute.org/cancer/
cga/mutect
VarScan v2.4.1 Koboldt et al., 2009 http://varscan.sourceforge.net/
Scalpel v0.5.3 Fang et al., 2016a https://github.com/hanfang/scalpel-protocol
Annovar Wang et al., 2010a http://annovar.openbioinformatics.org/
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Polysolver v1.0.0 Shukla et al., 2015 https://software.broadinstitute.org/cancer/
cga/polysolver
NetMHCpan v3.0 Andreatta and Nielsen, 2016 http://www.cbs.dtu.dk/services/
NetMHCpan-3.0/
NetMHC v4.0 Andreatta and Nielsen, 2016 http://www.cbs.dtu.dk/services/NetMHC/
Platypus v0.8.1 Rimmer et al., 2014 https://github.com/andyrimmer/Platypus
CNVkit v0.7.3 Talevich et al., 2016 https://github.com/et al./cnvkit
mapsplice v2.2.0 Wang et al., 2010b http://www.netlab.uky.edu/p/bioinfo/
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R package PSCBS v0.61.0 Olshen et al., 2011 https://cran.r-project.org/web/packages/
PSCBS/index.html
R package deconstructSigs v1.8.0 Rosenthal et al., 2016 https://github.com/raerose01/
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R package Copynumber v1.12.0 Nilsen et al., 2012 http://bioconductor.org/packages/release/
bioc/html/copynumber.html
R package ABSOLUTE v1.2 Carter et al., 2012 http://archive.broadinstitute.org/cancer/
cga/absolute
R package Rsamtools v1.3.1 Morgan et al., 2017 https://bioconductor.org/packages/release/
bioc/html/Rsamtools.html
bedtools package Quinlan and Hall, 2010 http://bedtools.readthedocs.io/en/latest/
STAR aligner v2.6.1 Dobin et al., 2013 https://github.com/alexdobin/STAR
RSEM v1.3.0 Li and Dewey., 2011 https://github.com/deweylab/RSEM
Hisat2 v.2.1.0 Kim et al., 2019 http://daehwankimlab.github.io/hisat2/
Subread package v.1.5.0 Liao et al., 2014 http://subread.sourceforge.net/
Lift Genome Annotations Tool N/A https://genome.ucsc.edu/cgi-bin/hgLiftOver
BLASTn Camacho et al., 2009 https://blast.ncbi.nlm.nih.gov/Blast.cgi?
PROGRAM=blastn&BLAST_SPEC=
GeoBlast&PAGE_TYPE=BlastSearch
DESeq2 Love et al., 2014 https://bioconductor.org/packages/release/
bioc/html/DESeq2.html
R package ‘XGR’ Fang et al., 2016b https://xgr.r-forge.r-project.org/
innate2adaptive/Decombinator N/A https://github.com/innate2adaptive/
Decombinator
R package ‘kernlab’ Karatzoglou et al., 2004 https://rdrr.io/cran/kernlab/
10x Genomics Cell Ranger 5.0.0 Zheng et al., 2017 https://support.10xgenomics.com/single-
cell-gene-expression/software/overview/
welcome
Seurat v.4.0.3 Stuart et al., 2019 https://satijalab.org/seurat/
SCTransform Hafemeister and Satija, 2019 https://github.com/ChristophH/sctransform
Harmony Korsunsky et al., 2019 https://portals.broadinstitute.org/harmony/
MAST Finak et al., 2015 https://www.bioconductor.org/packages/
release/bioc/html/MAST.html
scRepertoire Borcherding et al., 2020 https://github.com/ncborcherding/
scRepertoire
STARTRAC Zhang et al., 2018b https://github.com/Japrin/STARTRAC
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Materials availability
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Data and code availability
Raw bulk whole-exome sequencing, RNA-seq, and TCR-seq data have been deposited to the European Genome-phenome Archive
(Accession numbers +6+00001005638, EGAD00001008163, EGAD00001008165, respectively). Raw data for the single-cell RNA
and TCR-seq experiments have been deposited (EGAD00001008166). To facilitate ease of use, we have also deposited single-
cell count matrices, VDJ annotations, and metadata (https://doi.org/10.5522/04/16573640.v1), and processed bulk-TCR sequence
data (https://doi.org/10.5522/04/16571573.v1). Clinical data were obtained from the following sources: Yost et al. cohort (Yost et al.,
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Clinical studies
ADAPTeR (NCT02446860) is a single-arm, open-label, phase II study of nivolumab therapy as pre-operative therapy in metastatic
clear cell renal cell carcinoma (ccRCC). Planned interim analysis took place after six months after the last patient enrolled had their
first Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) defined objective response assessment. ADAPTeR was
initially approved by NRES Committee London Fulham on 01/12/2014. ADAPTeR is performed in accordance with the ethical prin-
ciples in the Declaration of Helsinki, Good Clinical Practice and applicable regulatory requirements.
Nivolumab was administered at a dose of 3mg per kilogram of body weight as a 60 minute intravenous infusion every 2 weeks.
Eligible patients were 18 years of age or older, had histologic confirmation of advanced ormetastatic ccRCCwith predominantly clear
cell component with at least one site of disease outside the kidney measurable according to the RECIST version 1.1, with no prior
systemic therapy for ccRCC. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Key
exclusion criteria were need for immediate nephrectomy, any active, known or suspected autoimmune disease or another condition
requiring systemic treatment with either corticosteroids (>10mg daily prednisolone equivalent) or other immunosuppressive medica-
tions within 14 days of study drug administration (excluding vitiligo, Type 1 diabetes mellitus, residual hypothyroidism due to auto-
immune condition only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to
recur in the absence of an external trigger). During the course of the study, inclusion expanded to those who have had a prior
nephrectomy but are suitable for on treatment biopsies. The prognostic factors assessed for the risk categorisation are as per the
published IMDC criteria (Heng et al., 2009): time to systemic therapy (<1 year), performance status, anaemia, hypercalcaemia, neu-
trophilia and thrombocytosis. Presence of zero (favourable-risk), one (intermediate-risk), and two or three (poor-risk) factors provides
the categorisation.
The primary endpoint was the safety profile of nivolumab given pre- and post-operatively to patients with metastatic ccRCC un-
dergoing nephrectomy. Secondary endpoints were overall response rate (ORR), progression free survival (PFS), and overall survival
(OS). Exploratory endpoints pertain to biomarker analyses. Patients deemed clinically suitable for nephrectomy at baseline were
scheduled for surgery after the fourth cycle of treatment. Patients not deemed clinically suitable for nephrectomy at baseline would
undergo surgery if an excellent clinical response is observed and if surgery was clinically appropriate. Nivolumab treatment was re-
commenced post-operatively upon sufficient recovery, and until disease progression. Patients who remained clinically unsuitable for
nephrectomy continued nivolumab treatment until disease progression.
For translational study sample collection, baseline tumour biopsy via appropriate guidance (ultrasound or computer tomography
[CT]) at least 3 days and up to 14 days prior to starting nivolumab was obtained. Tumour multiple regions of nephrectomy specimen
were sampled, as well as image guided biopsy of regressing lesions or at disease progression either at site of progression or, if not
possible, percutaneous primary renal tumour biopsy, prior to commencement of any subsequent treatment. Blood samples were
collected at each tumour sampling timepoint.
Autopsy samples from ADR001, ADR005, and ADR015 were obtained through the PEACE Study (NIHR 18422; NCT03004755),
where samples were harvested within 48 hours from death for these patients. All patients were co-recruited to the TRACERx Renal
study (NCT03226886; see secondary author list for the full list of TRACERx Renal consortium investigators). Patient and sample
metadata (i.e. age a diagnosis, sex, clinical response, biopsy site) are provided as Tables S1 and S2. All the patients provided written
informed consent. The protocols, amendments and informed consent forms were approved by the institutional review board or in-
dependent ethics committee at each trial site for each trial.
METHOD DETAILS
Sample collection
Tumour and normal tissue were collected via image-guided percutaneous biopsies, ex vivo sampling at nephrectomy, and at au-
topsy. Multi-region samples were obtained with all modalities. For samples obtained at nephrectomy, resected specimens were
reviewed macroscopically by a pathologist to guide multi-region sampling for this study and to avoid compromising diagnostic re-
quirements. Spatially separated regions sampled from the ‘‘tumour slice’’ using a 6mm punch biopsy needle. The punch was
changed between samples to avoid contamination. The total number of samples obtained reflects the tumour size with a minimum
of three biopsies that are non-overlapping and equally spaced. Areaswhich are obviously fibrotic or haemorrhagic are avoided during
sampling and every attempt is made to reflect macroscopically heterogeneous tumour areas. Primary tumour regions are labelled as
R1, R2, R3.Rn and locations are recorded. Normal kidney tissue was sampled from areas distant to the primary tumour and labelled
N1. For all samples collected, each were split into two for snap freezing and formalin fixing respectively, such that the fresh frozen
sample has its mirror image in the formalin-fixed sample which is subsequently paraffin embedded. Fresh samples were placed in a
1.8 ml cryotube and immediately snap frozen in liquid nitrogen for >30 seconds and transferred to -80 C for storage. Peripheral blood
was collected at the time of surgery and processed to separate buffy coat and peripheral blood mononuclear cells (PBMCs).
Nucleic acid extraction, DNA and RNA library preparation and sequencing
DNA and RNA were co-extracted from fresh-frozen tumour tissue using AllPrep DNA/RNA mini kit (Qiagen). RNA from peripheral
blood mononuclear cells (PBMC) were extracted from blood stored in Tempus tubes using the Tempus Spin RNA Isolation Kite4 Cancer Cell 39, 1–22.e1–e11, November 8, 2021
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were assessed on TapeStation4200 (Agilent) and Qubit Fluorometric quantification (ThermoFisher Scientific). Samples were normal-
ised to either 3 ug or 200ng and sheared to 150-200bp using a Covaris-E220 or LE220-plus. Agilent SureSelectXT enriched libraries
were constructed following the manufacturer’s manual or automated (using the Agilent Bravo liquid handling platform) SureSelectXT
Target Enrichment System for Illumina Paired-end Multiplexed Sequencing Library protocol. Hybridisation and capture were per-
formed using the Agilent SureSelectXT Human All Exon v5 capture library. Final libraries were sequenced to a target coverage of
250x with 101bp paired-end reads multiplexed on the Illumina HiSeq4000 sequencing platform. The extracted RNA was normalised
to 100ng for library construction using RNA-Ribozero (ribodeplete) Library Preparation Kits. The prepared libraries were multiplexed
and QC’ed before paired-end sequencing with target coverage of 50 million reads per sample on HiSeq4000 sequencing platforms
(Illumina). RNA was extracted from blood for TCR sequencing from the following cases and timepoints: all cases (n = 15) pre- and
post-treatment.
SNV, and INDEL calling from multiregion WE sequencing
Paired-end reads (2333100bp) in FastQ format sequenced byHiseqwere aligned to the reference human genome (build hg19), using
the Burrows-Wheeler Aligner (BWA) v0.7.15. with seed recurrences (-c flag) set to 10000(Li and Durbin, 2009). Intermediate process-
ing of Sam/Bam files was performed using Samtools v1.3.1 and deduplication was performed using Picard 1.81 (http://
broadinstitute.github.io/picard/). Single Nucleotide Variant (SNV) calling was performed using Mutect v1.1.7 and small scale inser-
tion-and-deletions (INDELs) were called running VarScan v2.4.1 in somaticmodewith aminimum variant frequency (–min-var-freq) of
0.005, a tumour purity estimate (–tumour-purity) of 0.75 and then validated using Scalpel v0.5.3 (scalpel-discovery in –somatic mode)
(intersection between two callers taken) (Fang et al., 2016a; Cibulskis et al., 2013; Koboldt et al., 2009). SNVs called by Mutect were
further filtered using the following criteria: i)%5 alternative reads supporting the variant and variant allele frequency (VAF) of%1% in
the corresponding germline sample, ii) variants falling into mitochondrial chromosome, HLA genes or any intergenic region were not
considered, iii) presence of both forward and reverse strand reads supporting the variant, iv) >5 reads supporting the variant in at least
one sample, v) variants were required to have a VAF of 0.01 in at least one sample, vi) sequencing depth need to beR20 and%3000
across all samples. Dinucleotide substitutions (DNV) were identified when two adjacent SNVs were called and their VAFs were
consistently balanced (based on proportion test, P R 0.05). In such cases the start and stop positions were corrected to represent
a DNV and frequency related values were recalculated to represent the mean of the SNVs. Variants were annotated using Annovar
(Wang et al., 2010a). Individual tumour biopsy regionswere judged to have failed quality control and excluded from analysis based on
the following criteria: i) sequencing coverage depth below 1003, ii) low tumour purity such that copy number calling failed. Driver
variants are manually reviewed and predicted for variant effect and variant annotations on the heatmap are only for confident driver
events.
Methylation specific PCR
Methylation of the VHL promoter was detected after bisulphite treatment of 500ng of patient DNA using the EZ DNA Methylation-
Direct kit (Zymo Research). Bisulphite treated DNA was amplified in the PCR using methylation specific oligonucleotides followed
by Big Dye terminator Sanger sequencing. Methylation was confirmed by comparing and contrasting patient tumour and normal
renal tissue for methylation protected CpG sequences. Oligonucleotide names and sequences 50-3’: VHL_methylation_1F (forward):
gagtttttttaggttattttttgtaat; VHL_methylation_1R (reverse): tcaccctaaatatatatcctacctcaaaa; VHL_methylation_2F: cccctctaaaatttaa-
tattttt; VHL_methylation_2R: ggttaaggttgtagtgagttaagtt.
Neoantigen calling
Neoantigen predictions were derived by first determining the 4-digit HLA type for each patient, along with mutations in class I HLA
genes, using POLYSOLVER (Shukla et al., 2015). Next, all possible 9, 10 and 11-mer mutant peptides were computed, based on the
detected somatic non-synonymous SNV and INDEL mutations in each sample. Binding affinities of mutant and corresponding wild-
type peptides, relevant to the corresponding POLYSOLVER-inferred HLA alleles, were predicted using NetMHCpan (v3.0) (Hoof
et al., 2008) and NetMHC (v4.0) (Andreatta and Nielsen, 2016). Neoantigen binders were defined as strong binders if their %rank
was below <0.5 for the mutant and >0.5 for the wildtype protein.
TMB, fsINDEL burden, neonatigen burden, wGII, ITH index
Tumour mutational burden (TMB) was calculated as the number of exonic non-synonymous SNVs per mega base. The frameshift
INDEL (fsINDEL) burden was calculated as the total number of exonic frameshift INDELs per sample. Clonal TMB/fsINDEL burden
was accordingly calculated as the number of ubiquitous non-synonymous SNVs/fsINDELs (shared by all samples) in multi-region
sampled cases and as the number of mutations with a CCF >0.5 for patients with single-region sampling. The neoantigen burden
was calculated as the total number of predicted strong binders per sample. The average proportion of the genome with aberrant
copy number, weighted on each of the 22 autosomal chromosomes, was estimated as the weighted genome instability index
(wGII). Maximum wGII for each patient (from multiregion sample sets) was used as overall tumour wGII. Overall ITH was measured
as an index (ITH index = # subclonal drivers/# clonal drivers, where ‘‘drivers’’ include all driver mutations and driver SCNAs shown in
Figure 1B).Cancer Cell 39, 1–22.e1–e11, November 8, 2021 e5
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Single nucleotide polymorphisms (SNPs) were called in the germline sample using Platypus v0.8.1 with default parameters apart from
–genIndels = 0 and –minMapQual = 40. Tumour regions were genotyped at positions where a SNP was detected in the germline (pa-
rameters set to –minPosterior = 0 –getVariantsFromBAMs = 0). SNPswith aminimumcoverage of 503 in the germline and the tumour
sample were used for allele-specific copy number segmentation.
Copy number analysis
CNVkit v0.7.3 was used with default parameters on paired tumour-normal sequencing data (Talevich et al., 2016). Outliers of the
derived log2-ratio (logR) calls from CNVkit were detected and modified using Median Absolute Deviation Winsorization before
case-specific joint segmentation of fresh-frozen samples to identify genomic segments of constant logR (Nilsen et al., 2012).
Formalin-fixed and paraffin-embedded (FFPE) samples were segmented separately while leveraging the segment information
from the fresh-frozen samples. Copy number alterations were called as losses or gains relative to overall sample wide estimated
ploidy. Driver copy number was identified by overlapping the called somatic copy number segments with putative driver copy num-
ber regions identified by Beroukhim et al. (Beroukhim et al., 2009). Allele-specific segmentation was performed using the paired
PSCBS method after removal of single-locus outliers (R package PSCBS v0.61.0) (Olshen et al., 2011).
Purity and ploidy estimate
Tumour sample purity, average ploidy and absolute allelic copy number per segment were estimated using ABSOLUTE v1.2 in allelic
mode (Carter et al., 2012). In line with recommended best practice all ABSOLUTE solutions were reviewed by 3 researchers, with
solutions selected based on majority vote. Purity assigned 0.1 for samples below ABSOLUTE estimate thresholds for comparison
analysis of samples between responders and non-responders.
Subclonal deconstruction
To estimate the CCF of a mutation, we used the following formula:
VAF =
CNmut  CCF  p
CNn  ð1 pÞ+CNt  p
Where VAF is the variant allele frequency of the mutation, p the estimated tumour purity, CNmut the number of copies carrying the
mutation and CNt the local copy number in the tumour cells. CNn is the local copy number in the non-tumour proportion of the sample
which was assumed to be 2. The CNmut and CCF were estimated through iteration of all possible combinations of CCF (range 0.01
to 1, by 0.01) and CNmut (range 1 to CNt, by 1) using the formula above to identify the best fit CCF.
Selection against neoantigen-encoding mutations
For each patient with matched pre- and post-treatment WES data (N = 8 patients), the CCFs of all nsSNVs and fsINDELs were
compared pre- and post-treatment. In patients withmultiple pre-treatment samples, median pre-treatment CCFswere used as base-
line. Amutation was defined to have undergonemutation depletion (‘genomic contraction’) (Riaz et al., 2017) if the CCF decreased by
R 10% from pre- to post-treatment or if the mutation was present in the pre-treatment but not the post-treatment sample. An enrich-
ment test (Fisher’s exact test) was performed to determine whethermutations which are predicted to encode neoantigens weremore
likely to undergo genomic contraction than the remaining nonsynonymous SNVs and frameshift INDELs.
Mutational signature analysis
Mutational signatures were estimated using the deconstructSigs package in R (Rosenthal et al., 2016). Sample specific mutational
signature analysis was restricted to samples with at least 50 mutations.
Analysis for mismatch repair deficiency
Analysis for mutations in the following nominated genes was performed: POLD3, MLH3, MSH6, RPA4, LIG1, MLH1, MSH2, MSH3,
PCNA, PMS2, POLD1, POLD2, POLD4, RFC1, RFC2, RFC3, RFC4, RFC5, RPA1, RPA2, RPA3, SSBP1, EXO1.
Analysis for mutations associated with defective antigen presentation
Analysis for mutations in the following nominated genes was performed: B2M, CIITA, IRF1, PSME1, PSME2, PSME3, ERAP1,
ERAP2, HSPA, PSMA7, HSPC, HSPBP1, TAP1, TAP2, TAPBP, CALR, CNX, CANX, PDIA3.
Detection of B2M mutations by Sanger sequencing
Validation of the B2M mutation was performed using PCR followed by Big Dye Terminator Sanger sequencing on the ABI 3700.
20ng of patient DNA was amplified for exon 1 of B2M, to enable detection of B2M:c.42_45delTCTT:p.S14fs. PCR conditions
involved 35 cycles of denaturation at 950C, followed by oligonucleotide primer annealing at 55C and sequence extension at
720C using Qiagen Taq polymerase and reagents. Oligonucleotide sequences used are: Forward: aacgggaaagtccctctctc; Reverse:
agatccagccctggactagc.e6 Cancer Cell 39, 1–22.e1–e11, November 8, 2021
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RNAseq data were mapped to the hg19 reference human genome using the STAR (Dobin et al., 2013) algorithm, and transcript and
gene abundancewere estimated byRSEM (Dobin et al., 2013) with default parameters. Sampleswere excluded if they had fewer than
15,000 genes detected.
Whole-transcriptome sequencing (RNA) variant calling
Insertion/deletion mutations were called from raw paired end FASTQ files, using mapsplice (v2.2.0), with sequence reads aligned to
hg19 genomic assembly (using bowtie pre-built index). MinimumQC thresholds were set to retain variants withR5 alternative reads,
and variant allele frequency R0.05. Insertions and deletions which were detected in both RNA and DNA sequencing assays for the
same sample were designated as expressed indels. SNVs in RNA sequencing data were called directly from the BAM files, using
Rsamtools to extract read counts per allele for each genomic position where a SNV had already been called in DNA sequencing anal-
ysis. Similarly, minimum QC thresholds ofR5 alternative reads, and variant allele frequencyR0.05, were used and variants passing
these thresholds were designated as expressed SNVs.
Human endogenous retrovirus (HERV) analysis
Expression of previously annotated HERVs (Rooney et al., 2015; Panda et al., 2018; Smith et al., 2018) was analysed. HERV loci used
in these three studies were taken from Mayer et al. (2011) and Vargiu et al. (2016) with 66 and 3173 loci respectively. BLASTn was
used to match example sequences from HERVs in Mayer et al. to GRCh38, chromosome coordinates with the greatest homology
over the greatest length were taken as the best match. The Lift Genome Annotations tool from UCSC (https://genome.ucsc.edu/
cgi-bin/hgLiftOver) was used to convert annotated GRCh37 HERV loci coordinates from Vargui et al. to GRCh38 coordinates.
Comparing the new coordinates, 47 of the 66 HERVs from Mayer et al. were present in the list of 3173. Coordinates of all the unique
elements were then compared to a custom repeat region annotation previously built using the Dfam 2.0 library (v150923) for GRCh38
(Attig et al., 2017). For this custom annotation, different regions of the same provirus (e.g. the LTR and internal genes) were annotated
separately, these regions were merged to allow accurate quantitation of reads from the same provirus (Attig et al., 2017). LTR-con-
taining repeat regions from the custom annotation had to begin, end, or be fully contained within previously annotated loci to be
considered a match, a buffer of 5 bases either end of the locus was included. Previously annotated HERV loci from Mayer et al.
and Vargiu et al. were found to overlap multiple repeat regions per locus in our custom annotations, or were found to overlap no
repeat regions at all. Some loci also overlapped other endogenous retroelement types such as LINEs and SINEs, as well as overlap-
ping canonical gene exons. For this analysis, only expression of matching LTR-containing elements was considered rather than
expression of all repeats and genes overlapping previously annotated loci. Reads were aligned to GRCh38 using Hisat2 (version
2.1.0), SAMtools (version 1.3.1) was used to convert the output to BAM files. Expression of LTR-containing elements was measured
using read counts calculated by the featureCounts function from the Subread package (Liao et al., 2014) (version 1.5.0, with param-
eters -p -C -B -f -T 2), multi-mapping reads were not counted. Analysis for purified immune cell subset expression were performed on
publicly available datasets from Linsley et al. (2014) (E-MTAB-8208 (EMBL-EBI)) and Kazachenka et al. (2019) (accession no.
GSE60424 (GEO)). LTR-overlapping transcripts expressed highly specifically in ccRCC were previously described (Attig et al.,
2019). These transcripts were identified through de novo transcriptome assembly and their expression quantified in by transcript
per million calculations, as previously described (Attig et al., 2019).
Differential gene expression analysis, pathway analysis and gene set enrichment
DESeq2 (Love et al., 2014) was used for differential expression analysis, using the binomial Wald test after estimation of size factors
and estimation of dispersion. To identify genes differentially expressed between responders and non-responders, we considered
only transcripts with normalized count number >5 in at least 5 patients. Pathway analysis was performed using the R package
XGR (Fang et al., 2016b) using the gene ontology biological process (GOBP) databases. Induced and suppressed transcripts
were analysed separately against the background of all tested transcripts. The ‘‘lea’’ ontology algorithm was used.
T cell subset gene signature
Gene signature or single gene enrichment was evaluated using RSEM abundance, z score scaled across all samples for which RNA-
Seq was available. Signature analysis was performed using 22 immune-related signatures listed below: i) the Danaher immune score
is a 60-marker gene signature derived from pan-cancer RNAseq analysis for 14 immune cell populations, where marker genes have
been benchmarked against histological tumour-infiltrating lymphocyte (TIL) estimates and flow cytometry data (Rosenthal et al.,
2019; Danaher et al., 2017); ii) IMmotion150 (McDermott et al., 2018); iii) Javelin101 (Motzer et al., 2019).
(1) Danaher T cells: CD3D, CD3E, CD3G, CD6, SH2D1A, TRAT1
(2) Danaher CD8: CD8A, CD8B
(3) Danaher Cytotoxic: CTSW, GNLY, GZMA, GZMB, GZMH, KLRB1, KLRD1, KLRK1, PRF1, NKG7
(4) Danaher B cells: BLK, CD19, MS4A1, TNFRSF17, FCRL2, KIAA0125, PNOC, SPIB, TCL1A
(5) Danaher NK cells: NCR1, XCL2, XCL1
(6) Danaher CD45: PTPRC
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(9) Danaher Mac: CD163,CD68, CD84, MS4A4A
(10) Danaher Mast: MS4A2,TPSAB1,CPA3,HDC,TPSB2
(11) Danaher Neut: CSF3R, S100A12, CEACAM3, FCAR, FCGR3B, FPR1, SIGLEC5
(12) Danaher NKCD56: IL21R, KIR2DL3, KIR3DL1, KIR3DL2
(13) Danaher Th1: TBX21
(14) Danaher Treg: FOXP3
(15) IMmotion150 Angio: VEGFA, KDR, ESM1, PECAM1, ANGPTL4, CD34
(16) IMmotion150 Teff: CD8A, IFNG, PRF1, EOMES, CD274
(17) IMmotion150 Myeloid: CXCL1, CXCL2, CXCL3, CXCL8, IL6, PTGS2
(18) Javelin101 TCR: CD3G, CD3E, CD8B, THEMIS, TRAT1, GRAP2, CD247
(19) Javelin101 T cell: CD2, CD96, PRF1, CD6, IL7R, ITK, GPR18, EOMES, SIT1, NLRC3
(20) Javelin101 NK: CD2, CD96, PRF1, CD244, KLRD1, SH2D1A
(21) Javelin101 chemo: CCL5, XCL2
(22) Javelin101 other: CST7, GFI1, KCNA3, PSTPIP1
The signature score was calculated as the arithmetic mean of z score scaled expression of all genes in that signature for each
sample.TCR sequencing
TCR b-chain sequencing was performed by utilizing whole RNA extracted from tissue samples or from cryopreserved PBMC sam-
ples, by using a quantitative experimental and computational TCR sequencing pipeline described previously (Best et al., 2015; Oakes
et al., 2017; Thomas et al., 2013; Uddin et al., 2019). An important feature of this protocol is the incorporation of a UMI attached to
each cDNA TCR molecule that enables correction for PCR and sequencing errors, which allows higher quantitative precision
compared to alternate protocols in the TCR sequences retrieved (Oakes et al., 2017; Barennes et al., 2020). The suite of tools
used for TCR identification, error correction and CDR3 extraction is freely available at https://github.com/innate2adaptive/
Decombinator.
For each TCR, we computed the abundance as the count of UMIs mapping to this TCR divided by the total number of UMIs in the
sample. If several samples were available at a given patient-timepoint pair, the resulting abundance was calculated as the sum of
counts for this TCR across the available samples divided by the sum of total counts across these samples.
Repertoire similarity measure
The similarity between two TCR repertoires was assessed with the normalised dot product (also known as the cosine similarity) be-
tween the vectors of TCR abundance. This measure is a well-established metric widely used in machine learning to compare numer-
ical vectors and gives a value between 0 (no similarity, that is, orthogonal vectors) and 1 (complete similarity, from vectors with an
identical magnitude and direction in the feature space). Each pair of repertoires is represented as two vectors of equal length, indexed
by the union of TCRs found in both repertoires and containing the number of times each TCR is detected in each of the two repertoires




where and are the abundance vectors, represents the vector product and paired vertical bars represent the Euclidean norm of the
vector.
For longitudinal similarity (Figures 5D, S7G, and S8B), the similarity measure was performed on the TCR abundance vectors
derived from (patient, timepoint) pairs.
For spatial similarity (Figures S7A and S7B), the similarity measure was performed on the TCR abundance vectors derived from
each sample within a (patient, timepoint) pair. For this analysis, samples from different timepoints were not compared.
Repertoire clonality index
The clonality index was estimated for each sample by using the command entropy from the entropy R package, on the basis of the
observed frequency of the TCRs in that sample
Clonality = 1 
X
pi 3 log pi
.
ln N
where pi is the frequency of the ith TCR in the repertoire and is the number of TCRs in that repertoire.
Classification of expanded, contracted and persistent TCRs
The difference in abundance between Pre-treatment andOn-treatment was calculated with the poisson.test function in R, as the data
were counts. TCRs with P values above 0.01 were labelled as persistent.Cancer Cell 39, 1–22.e1–e11, November 8, 2021
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Wecounted the number of TCRs detected with frequencies above a range of frequency thresholds in the tumour repertoires. Tomea-
sure how such defined expanded TCRs were representative of the shape of the TCR distribution captured by the clonality score, we
computed the prevalence of the expanded population amongst the entire repertoire, for each threshold. To do so, we took the sum of
counts for expanded TCRs and divided it by the sum of all counts in the sample. The proportion obtained was then correlated to the
matched clonality score with the Spearman’s rank correlation.
To focus on the most expanded TCRs (Figures 5C, 5E, S7E, and S7F), we examined those present above a threshold frequency of
2/1,000 (corresponding to the top 1% of the empirical TCR frequency distribution). At this threshold, which we already described in
previously published work (Barennes et al., 2020), the correlation between clonality and proportion of repertoire occupied by
expanded TCRs is very strong and the number of TCRs labelled as expanded is greater than for higher thresholds for which this cor-
relation is also significant, which enables to keep the greatest amount of data whilst still applying a stringent filtering step.
CDR3 amino acid clustering
The pairwise similarity between pairs of TCRs was measured on the basis of amino acid triplet sharing. Sharing was quantified using
the normalized string kernel function stringdot (with parameters stringdot (type = ‘spectrum’, length = 3, normalized = TRUE) from the
Kernlab package. The kernel is calculated as the number of amino acid triplets (sets of three consecutive amino acids) shared by two
CDR3s, normalized by the number of triplets in each CDR3 being compared. The TCR similarity matrix was converted into a network
diagram by using the iGraph package in R. Two TCRs were considered connected if the similarity index was >0.82 (threshold pre-
viously optimised in a separate study).
Per (patient, timepoint) pair, we counted the number of clusters containing an expanded CDR3. To normalize the counts of clusters
obtained (Nreal) for the input size, for each sample, we randomly selected, outside of the real clustering structure, the number of
CDR3s equal to the number of expanded CDR3s in that sample and looked for clusters around those. This control step was repeated
10 times for each (patient, timepoint) pair and we computed the average number of clusters obtained for those control (Ncon) and
used Nreal=Ncon as the normalised cluster count value.
We used the clustering structure built as described above for pre-treatment samples and retrospectively labelled expanded clones
at that time-point as maintained if they were also expanded post-treatment or as replaced if they were not. By doing so, we could
derive the number of pre-treatment clusters containing maintained (resp. replaced) expanded clones which was then divided by
the initial count of maintained (resp. replaced) expanded clones present in that sample to obtain the proportion displayed.
Frequency ratio
Wewanted to capture the rate of clonal replacement that occurs in the tumour repertoires. To do so, for each expanded TCR at base-
line that could also be detected after treatment, we computed the ratio of the observed frequency at baseline divided by the observed
frequency after-treatment. To derive a metric for each patient, we computed the average of ratio scores obtained for all expanded
TCRs at baseline (those that could not be detected after treatment were excluded).
Analysis of Yost et al. cohort Bulk TCR sequencing data from Yost et al. (2019) were retrieved from Adaptive Biotechnologies’
ImmuneACCESS database (https://doi.org/10.21417/KY2019NM; https://clients.adaptivebiotech.com/pub/yost-2019-natmed). In-
tratumoural longitudinal similarity wasmeasured with the cosinemetric for 11 patients split between responders and non-responders
as defined in their original work. See Table S4 for patient and sample annotations.
Multiplex immunofluorescence staining and image analysis
Formalin-fixed paraffin-embedded (FFPE) blocks were cut in 2 micron thick slides. The slides were baked for 60 minutes and stained
using the antibodies listed below and opal fluorophores. Leica Bond III machine was used for the immunofluorescence staining. Im-
ages of the stained slides were acquired by using the Vectra 3 automated quantitative pathology imaging system (Akoya Biosci-
ences). Matching haematoxylin and eosin (H&E) image of each slide was reviewed by a pathologist and areas to annotate on the
immunofluorescent images for analysis were identified. Necrotic and stromal areas as well as non-tumour areas were excluded
and tumour areas were scored. Slides for patient ADR009 were not evaluable due to necrosis. Total of 61 samples (41 pre-treatment
and 20 on treatment samples) for the first mIF panel and 60 samples (40 pre-treatment and 20 on treatment samples) were for the
second IF panel were used for analysis. The following antibodies were used for mIF staining: CD3 (Mouse monoclonal, LN10,
1:100 dilution on Opal 520 in 1:50 dilution), CD4 (Mouse monoclonal, 4B12, 1:50 dilution on Opal 540 in 1:100 dilution), CD8 (Mouse
monoclonal, 4B11, 1:100 dilution on Opal 540 in 1:150 dilution and on Opal 620 in 1:150 dilution), FOXP3 (Mouse Monoclonal,
236A/E7, 1:80 dilution on Opal 570 in 1:150 dilution), CD163 (Mouse monoclonal, 10D6, 1:100 dilution on Opal 690 in 1:50 dilution),
Granzyme B (Mouse monoclonal, 11F1, 1:80 dilution, on Opal 620 in 1:150 dilution)
Up to 25multispectral images (MSI) were acquired per slide depending on the size of the tumour to include all representative areas
of the tumour. Representative MSIs from different slides were used while training the algorithms for each marker. Scoring of each
slide was performed using the inForm software on Vectra. The quality and accuracy of the scoring was checked by two clinicians
one of whom was a histopathologist. MSIs with poor tissue quality were excluded from the analysis. Merged data obtained by using
the inForm software was analysed using the phenoptrReports tool (Akoya Biosciences) on R. T cells subsets (CD8+, CD4+ effectors,
Tregs and CD8+CD4+ double positive cells) were scored both out of total cells counted on each slide and out of the total T cells
counted. CD163 cells were scored out of total cells counted per slide. Overall granzyme expression was scored in relation to the totalCancer Cell 39, 1–22.e1–e11, November 8, 2021 e9
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The mIF and mIHC antibody panels were designed to evaluate T cell subsets, B cells, myeloid cells, and GZMB expression. This
was conducted given 1) double positive (CD8+CD4+) T cells with high degrees of TCR clonality have previously been described in
ccRCC (Menard et al., 2018); 2) myeloid inflammation has been associated with blunting of anti-tumour T cell activity in metastatic
ccRCC (McDermott et al., 2018); and 3) high tumor infiltration with B cells and plasma cells have previously been shown to correlate
with favourable clinical outcomes across cancer types (Berntsson et al., 2016; Kroeger et al., 2016; Yeong et al., 2018).
Immunohistochemistry
FFPE tissue sections of clear cell renal cell carcinoma and normal tonsil tissues were subjected to H&E and multiplex immunostaining.
Theprimary antibodiesused formultiplex immunolabelingare as follows:CD19 (rabbitmonoclonal, SP291,1:10dilution),CD138 (mouse
monoclonal, MI15, 1:100 dilution), PD-1 (mouse monoclonal, NAT105/E3, 1:2 dilution). MLH1 (mouse monoclonal, WH0004292M2,
1:750 dilution) and B2M (rabbit monoclonal, 4H5L6, 1:500 dilution) were used as single stains on tissue from ADR015 separately.
To establish optimal staining conditions each antibody was tested and optimized on 2–4 um cut tissue sections of human reactive
tonsil and normal kidney by applying conventional single immunohistochemistry. In brief sections were de-waxed and re-hydrated
prior to themultiplex immunolabeling whose procedure was adapted and performed according to the established protocol described
elsewhere (Marafioti et al., 2003). Total of 59 samples (40 pre-treatment and 19 on treatment samples) for the mIHC panel.
Staining assessment and data handling
Specificity of the staining was assessed by a haematopathologist with expertise in multiplex-immunostaining. Scanned slide images
were obtained with the use of NanoZoomer Digital Pathology System (Hamamatsu, Japan). Total of 60 samples (41 pre-treatment
and 19 on treatment samples) were used for analysis.
Flow cytometry
Renal tumour resections and normal tissue were cut into small pieces (2-3mm) by using sterile disposable scalpel plus forceps in
RPMI (Sigma-Aldrich) with Collagenase I (Sigma-Aldrich) (for ADR013 tumour and normal tissue), Liberase (for ADR001 tumour tis-
sue) and DNAse I (Roche) and was digested for 1 hour at room temperature using the gentleMACS dissociator (Miltenyi Biotec). The
digest was passed through a 70-mm cell strainer by using 5-10 ml of RPMI containing 2% fetal bovine serum (FBS) to obtain a single-
cell suspension. Lymphocytes were obtained from the single-cell suspension by using Ficoll Paque Plus (GE Healthcare) density
gradient centrifugation (750g for 10 min). Isolated lymphocytes were washed with RPMI and 2%FBS and cryopreserved in 90%
FBS with 10% dimethyl sulfoxide (Sigma–Aldrich). PBMCs were isolated from blood samples collected in Vacutainer EDTA blood
collection tubes (BD) using Ficoll Paque Plus (GE Healthcare) density gradient centrifugation and cryopreserved in in 90% FBS
with 10% dimethyl sulfoxide (Sigma–Aldrich).
Thawed lymphocytes were washed with 13 phosphate-buffered saline (PBS) and were stained with the antibodies listed below.
Antibody mastermixes were prepared in Brilliant Staining Buffer (BD). eBioscience Foxp3/Transcription Factor Staining Buffer Set
was used for the intracellular staining. Samples were stained using the following antibodies: CD8 (RPA-T8, BUV496), CD45RA (HI100,
BUV563), CD4 (SK3, BUV615), CD38 (HIT2, BUV737), CD3 (SK7, BV705), FOXP3 (206D, BV421), CCR4 (L291H4, BV510), Viability
dye (Yellow Fluorescent reactive dye, BV570), CD57 (QA17A04, BV605), Ki67 (B56, BV650), CD39 (TU66, BV711), CCR7
(G043H7, BV750), CD69(FN50, BV785), CD103 (Ber-ACT8, BB515), CXCR5 (RF8B2, PerCp-Cy5-5), TCF-7 (7F11A10, PE), Granzyme
B (GB11, PE-CF594), CD25 (M-A251, PE-Cy5), PD-1 (EH12.2H7, PE-Cy7), TOX (REA473, APC), IgG4 (Biotin), 4-1BB (4B4-1,
BUV661), TIM-3 (7D3, BV650), Streptavidin (BUV395). The samples were acquired on the BD Symphony flow cytometer. Data
was analysed using the FlowJo (version 10).
PD-1 competition binding assay to evaluate anti-PD1 monoclonal antibody binding
PBMC isolated from healthy individuals were activated in vitro using plate coated anti-CD3 and soluble anti-CD28 with 100IU IL-2 per
well. 50ul (5ug/mL solution) anti-CD3 was used to coat wells of a 96 well plate which was kept at 4C overnight. Two washes using
200ul of PBS were performed to remove unbound antibodies the next day. Subsequently, 23 105 PBMC were added into each well
with subsequent addition of soluble anti-CD28 (2ug/mL). The plate was placed into a humidified 37C incubator for 72 hours.
Following this period, the wells containing activated PBMC were either incubated with 50ul (2.5mg) pembrolizumab or PBS control
for 30 minutes. PBS washes were used to remove unbound therapeutic antibodies. Flow cytometric staining of CD3, PD1 and anti-
IgG4 was performed thereafter.
Single-cell RNA/TCR sequencing
Tumour infiltrating lymphocytes fromADR001 andAD013were stainedwith CD3 (PE, SK7 clone), IgG4 (Biotinylated) and Streptavidin
(BV650) antibodies for flow cytometry. Stained cells were FACS sorted as CD3+IgG4- (40,000 cells) and CD3+IgG4+ (20,000 cells) for
ADR001 and CD3+IgG4- (50,000 cells) and CD3+IgG4+ (90,000 cells) for ADR013. FACS sorted cells were single-cell sorted using the
10X Genomic machine. The sorted cells were processed using the 10X Genomic ChromiumNext GEMSingle Cell 5’ Reagents Kit V2
(dual index) for 5’gene expression library construction and V(D)J library construction. The samples were sequenced on the NextSeq
using the High Output Kit v2.5 (150 Cycles).e10 Cancer Cell 39, 1–22.e1–e11, November 8, 2021
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were aligned to GRCh38 and counted using cellranger count, VDJ reads were aligned to cellranger’s GRCh38 VDJ reference dataset
using cellranger vdj. Expression matrices were analysed using the Seurat package (Stuart et al., 2019). To remove technical variation
in the data, TCR, ribosomal and heat-shock protein genes were removed from the analysis, also cells with mitochondrial reads mak-
ing up >10% total read content were removed. 8382 CD3+IgG4- and 10083 CD3+IgG4+ cells in ADR013; and 4648 CD3+IgG4- and
3343CD3+IgG4+ cells in ADR001were retained after quality control filtering. Datasets were integrated using SCTransform integration
(Hafemeister and Satija, 2019) using the recommended parameters and regressing the % mitochondrial read content. Principal
component analysis (PCA) and uniform manifold approximation and projection (UMAP) dimensional reduction (dims = 1:30) was
then performed using RunPCA and RunUMAP. Publicly available gene signatures for T cell states were obtained from the following
publications: Schietinger et al. (2016), Thommen et al. (2018), Guo et al. (2018), Li et al. (2019a), Yost et al. (2019), Miller et al. (2019),
Zhou et al. (2010), and Litchfield et al. (2021) (Table S4). The proportion of reads mapping to the genes in each signature for each cell
was then calculated using PercentageFeatureSet. All differential gene expression analysis were carried out on log normalised gene
expression values (using NormalizeData, default parameters) using the MAST algorithm (Finak et al., 2015) within FindMarkers.
GOBP analysis was carried out using the XGRpackage (Fang et al., 2016b) using the ‘‘lea’’ algorithm. scTCRdata was analysed using
scRepertoire. Cells were considered of the same clone if they contained a matching TRB sequence and CDR3 gene.
scRNA/TCRseq meta-analysis
Raw count matrices and scTCR annotations were downloaded from Braun et al. (2021) (downloaded from the published supple-
mental data), Borcherding et al. (2021) (Gene Expression Omnibus accession: GSE121638) and Krishna et al. (2021) (https://
trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?analysis=SRZ190804). Cells and genes in the ADR001 and ADR013 samples were filtered
as described previously. All samples were then filtered for CD8, CD4 and Tregs using expression cutoffs (countsR1 considered pos-
itive for each gene; CD8 = CD8A+CD4FOXP3-, CD4 = CD8ACD4+FOXP3-, Treg = CD8ACD4+FOXP3+). All samples were merged
into a single Seurat object, which was then processed using NormalizeData and FindVariableFeatures (default settings), then
ScaleData with % mitochondrial transcript being regressed, followed by RunPCA. Harmony based integration (Korsunsky et al.,
2019) was then used (through the Seurat wrapper RunHarmony) to batch correct the samples (patient was used as the batch variable,
kmeans_init_nstart = 20, kmeans_init_iter_max = 100). Harmony integration was chosen over Seurat integration (used in the ADR001
and ADR013 analysis) due to Harmony’s better performance with numerous batches. RunUMAP was then run using the Harmony
reduction and dims = 1:30. All differential gene expression analysis were carried out using the MAST algorithm (Finak et al., 2015)
within FindMarkers. TCR expansion was calculated. TCR expansion was calculated (based on TRB only) for each patient using
the ‘‘expa’’ metric from STARTRAC (Zhang et al., 2018b).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed in R and GraphPad Prism 8. Correlation was carried out with the Spearman’s rank correlation test.
We usedmixed effect modelling when appropriate. We used theMann–Whitney two-tailed paired or non-paired nonparametric tests
(as appropriate) to determine whether two independent samples were selected from the same population. P values were considered
significant if less than 0.05, and significance values were corrected for multiple testing by Bonferroni correction when appropriate.
High dimensional flow cytometry analysis was performed using FlowJo 10. Analyses and visualization of HERV expression were
additionally performed in Qlucore Omics Explorer (Qlucore, Lund, Sweden). Data visualization was performed in BioRender,
R and GraphPad Prism 8.
ADDITIONAL RESOURCES
Clinical trial registry numbers:
ADAPTeR: https://clinicaltrials.gov/ct2/show/NCT02446860.
TRACERx Renal: https://clinicaltrials.gov/ct2/show/NCT03226886.
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